Author: "Pallier C" / Publication Year Range: Last 10 years - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Pallier C"' showing total 100 results

Start Over Author "Pallier C" Publication Year Range Last 10 years

100 results on '"Pallier C"'

1. Impact of the mutational load on the virological response to a first-line rilpivirine-based regimen.

Author: Dimeglio, Chloé, Raymond, Stéphanie, Nicot, Florence, Jeanne, Nicolas, Carcenac, Romain, Lefebvre, Caroline, Izopet, Jacques, Roussel, C, Guillou-Guillemette, H Le, Alloui, C, Bettinger, D, Pallier, C, Fleury, H, Bellecave, P, Recordon-Pinson, P, Payan, C, Vallet, S, Vabret, A, Dina, J, Henquell, C, Mirand, A, Bouvier-Alias, M, de Rougemont, A, Si-Mohammed, A, Santos, G Dos, Morand, P, Signori-Schmuck, A, Bocket, L, Rogez, S, Andre, P, Tardy, JC, Trabaud, MA, Tamalet, C, Delamare, C, Montes, B, Schvoerer, E, Jeulin, H, Ferré, V, Rodallec, A, Guen, L Le, Cottalorda, J, Guinard, J, Guiguon, A, Descamps, D, Charpentier, C, Visseaux, B, Peytavin, G, Krivine, A, Bouviers-Alias, M, Avettand-Fenoel, V, Marcelin, AG, Calvez, V, Soulié, C, Wirden, M, Morand-Joubert, L, Lambert-Niclot, S, Fofana, D, Delaugerre, C, Chaix, ML, Mahjoub, N, Amiel, C, Schneider, V, Giraudeau, G, Beby-Defaux, A, Brodard, V, Maillard, A, Plantier, JC, Mourez, T, Leoz, M, Chaplain, C, Bourlet, T, Fafi-Kremer, S, Stoll-Keller, F, Schmitt, MP, Barth, H, Yerly, S, Poggi, C, Izopet, J, Raymond, S, Barin, F, Chaillon, A, Marque-Juillet, S, Roque-Afonso, AM, Haïm-Boukobza, S, Flandre, P, Grudé, M, Assoumou, L, and Costagliola, D
Subjects: Clinical Research, Genetics, HIV/AIDS, Infectious Diseases, Infection, Antiretroviral Therapy, Highly Active, Drug Resistance, Viral, Female, Genome, Viral, Genotype, HIV Infections, HIV-1, High-Throughput Nucleotide Sequencing, Humans, Male, Mutation, Rilpivirine, Treatment Outcome, Viral Load, French National Agency for Research on AIDS and Viral Hepatitis (ANRS) AC11 Resistance Study Group, Microbiology, Medical Microbiology, Pharmacology and Pharmaceutical Sciences
Abstract: ObjectivesTo determine how the load of rilpivirine-resistant variants (mutational load) influences the virological response (VR) of HIV-1-infected patients to a rilpivirine-based first-line regimen.Patients and methodsFour hundred and eighty-nine patients infected with HIV-1 whose reverse transcriptase gene had been successfully resistance genotyped using next-generation sequencing were given a first-line regimen containing rilpivirine. Variables associated with the VR at 12 months were identified using a logistic model. The results were used to build a multivariate model for each mutational load threshold and the R2 variations were analysed to identify the mutational load threshold that best predicted the VR.ResultsThe mutational load at baseline was the only variable linked to the VR at 12 months (P 1700 copies/mL and to 50% when the mutational load was > 9000 copies/mL. The threshold of 9000 copies/mL was associated with the VR at 12 months with an OR of 36.7 (95% CI 4.7-285.1). The threshold of 1700 copies/mL was associated with the VR at 12 months with an OR of 7.2 (95% CI 1.4-36.8).ConclusionsThere is quantifiable evidence that determining a mutational load threshold can be used to identify those patients on a first-line regimen containing rilpivirine who are at risk of virological failure. The clinical management of HIV-infected patients can be improved by evaluating the frequency of mutant variants at a threshold of
Published: 2019

2. Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen

Author: Raymond, Stéphanie, Nicot, Florence, Pallier, Coralie, Bellecave, Pantxika, Maillard, Anne, Trabaud, Mary Anne, Morand-Joubert, Laurence, Rodallec, Audrey, Amiel, Corinne, Mourez, Thomas, Bocket, Laurence, Beby-Defaux, Agnès, Bouvier-Alias, Magali, Lambert-Niclot, Sidonie, Charpentier, Charlotte, Malve, Brice, Mirand, Audrey, Dina, Julia, Le Guillou-Guillemette, Hélène, Marque-Juillet, Stéphanie, Signori-Schmuck, Anne, Barin, Francis, Si-Mohamed, Ali, Fenoel, Véronique Avettand, Roussel, Catherine, Calvez, Vincent, Saune, Karine, Marcelin, Anne Geneviève, Rodriguez, Christophe, Descamps, Diane, Izopet, Jacques, Lagier, E, Roussel, C, Le Guillou-Guillemette, H, Alloui, C, Bettinger, D, Pallier, C, Fleury, H, Reigadas, S, Bellecave, P, Recordon-Pinson, P, Payan, C, Vallet, S, Vabret, A, Dina, J, Henquell, C, Mirand, A, Bouvier-Alias, M, de Rougemont, A, Dos Santos, G, Morand, P, Signori-Schmuck, A, Bocket, L, Rogez, S, Andre, P, Tardy, JC, Trabaud, MA, Tamalet, C, Delamare, C, Montes, B, Schvoerer, E, Ferré, V, André-Garnier, E, Cottalorda, J, Guinard, J, Guiguon, A, Descamps, D, Brun-Vézinet, F, Charpentier, C, Visseaux, B, Peytavin, G, Krivine, A, Si-Mohamed, A, Avettand-Fenoel, V, Marcelin, AG, Calvez, V, Lambert-Niclot, S, Soulié, C, Wirden, M, Morand-Joubert, L, Delaugerre, C, Chaix, ML, Amiel, C, Schneider, V, Giraudeau, G, Defaux, A Beby-, Brodard, V, Maillard, A, Plantier, JC, Chaplain, C, Bourlet, T, Fafi-Kremer, S, Stoll-Keller, F, Schmitt, MP, Barth, H, Yerly, S, Poggi, C, Izopet, J, Raymond, S, and Barin, F
Subjects: Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Immunology, Antimicrobial Resistance, Genetics, HIV/AIDS, Clinical Research, Infectious Diseases, Aetiology, 2.1 Biological and endogenous factors, Infection, Good Health and Well Being, Adult, Drug Resistance, Viral, Female, Genetic Variation, HIV Infections, HIV-1, Humans, Male, Mutation, Rilpivirine, Viral Load, minority resistant variants, rilpivirine, first-line antiretroviral therapy, ultra-deep sequencing, French National Agency for Research on AIDS and Viral Hepatitis (ANRS) AC11 Resistance Study Group, Biological Sciences, Medical and Health Sciences, Microbiology, Clinical sciences
Abstract: BackgroundMinority resistant variants of human immunodeficiency virus type 1 (HIV-1) could influence the virological response to treatment based on nonnucleoside reverse transcriptase inhibitors (NNRTIs). Data on minority rilpivirine-resistant variants are scarce. This study used next-generation sequencing (NGS) to identify patients harboring minority resistant variants to nucleos(t)ide reverse transcriptase inhibitors and NNRTIs and to assess their influence on the virological response (VR).MethodsAll the subjects, 541 HIV-1-infected patients started a first-line regimen containing rilpivirine. VR was defined as a HIV-1 RNA load 20% in 29% of samples. We identified 43 (8.8%) and 36 (7.4%) patients who harbored rilpivirine-resistant variants with a 1% sensitivity threshold according to the French National Agency for Research on AIDS and Viral Hepatitis and Stanford algorithms, respectively. The VR was 96.9% at month 12. Detection of minority rilpivirine resistant variants was not associated with virological failure (VF). Multivariate analysis indicated that VF at month 12 was associated with a CD4 count
Published: 2018

3. Seeing inferences: brain dynamics and oculomotor signatures of non-verbal deduction

Author: Martín-Salguero, A, Reverberi, C, Solari, A, Filippin, L, Pallier, C, Bonatti, L, Martín-Salguero A., Reverberi C., Solari A., Filippin L., Pallier C., Bonatti L. L., Martín-Salguero, A, Reverberi, C, Solari, A, Filippin, L, Pallier, C, Bonatti, L, Martín-Salguero A., Reverberi C., Solari A., Filippin L., Pallier C., and Bonatti L. L.
Abstract: We often express our thoughts through words, but thinking goes well beyond language. Here we focus on an elementary but basic thinking process, disjunction elimination, elicited by elementary visual scenes deprived of linguistic content, describing its neural and oculomotor correlates. We track two main components of a nonverbal deductive process: the construction of a logical representation (A or B), and its simplification by deduction (not A, therefore B). We identify the network active in the two phases and show that in the latter, but not in the former, it overlaps with areas known to respond to verbal logical reasoning. Oculomotor markers consistently differentiate logical processing induced by the construction of a representation, its simplification by deductive inference, and its maintenance when inferences cannot be drawn. Our results reveal how integrative logical processes incorporate novel experience in the flow of thoughts induced by visual scenes.
Published: 2023

4. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients

Author: Fourati, Slim, Charpentier, Charlotte, Amiel, Corinne, Morand-Joubert, Laurence, Reigadas, Sandrine, Trabaud, Mary-Anne, Delaugerre, Constance, Nicot, Florence, Rodallec, Audrey, Maillard, Anne, Mirand, Audrey, Jeulin, Hélène, Montès, Brigitte, Barin, Francis, Bettinger, Dominique, Le Guillou-Guillemette, Hélène, Vallet, Sophie, Signori-Schmuck, Anne, Descamps, Diane, Calvez, Vincent, Flandre, Philippe, Marcelin, Anne-Genevieve, Lagier, E, Roussel, C, Le Guillou, H, Alloui, C, Bettinger, D, Pallier, C, Fleury, H, Reigadas, S, Bellecave, P, Recordon-Pinson, P, Payan, C, Vallet, S, Vabret, A, Henquell, C, Mirand, A, Bouvier-Alias, M, de Rougemont, A, Dos Santos, G, Morand, P, Signori-Schmuck, A, Bocket, L, Rogez, S, Andre, P, Tardy, JC, Trabaud, MA, Tamalet, C, Delamare, C, Montes, B, Schvoerer, E, Ferre, V, André-Garnier, E, Cottalorda, J, Guinard, J, Guiguon, A, Descamps, D, Brun-Vézinet, F, Charpentier, C, Visseaux, B, Peytavin, G, Krivine, A, Si-Mohamed, A, Avettand-Fenoel, V, Marcelin, AG, Calvez, V, Lambert-Niclot, S, Soulié, C, Wirden, M, Morand-Joubert, L, Delaugerre, C, Chaix, ML, Amiel, C, Schneider, V, Giraudeau, G, Brodard, V, Maillard, A, Plantier, JC, Chaplain, C, Bourlet, T, Fafi-Kremer, S, Stoll-Keller, F, Schmitt, MP, Barth, H, Yerly, S, Poggi, C, Izopet, J, Raymond, S, Barin, F, Chaillon, A, Marque-Juillet, S, Roque-Afonso, AM, Haïm-Boukobza, S, Flandre, P, Grudé, M, Assoumou, L, Costagliola, D, Allegre, T, Schmit, JL, and Chennebault, JM
Subjects: Medical Microbiology, Biomedical and Clinical Sciences, Infectious Diseases, Genetics, Aetiology, 2.1 Biological and endogenous factors, Infection, Adult, Anti-HIV Agents, Drug Resistance, Viral, Female, France, HIV Infections, HIV Integrase, HIV Protease, HIV Reverse Transcriptase, HIV-1, Heterocyclic Compounds, 3-Ring, Humans, Male, Middle Aged, Mutant Proteins, Oxazines, Piperazines, Pyridones, Quinolones, Raltegravir Potassium, Sequence Analysis, DNA, integrase, inhibitors, mutations, patterns, ANRS AC11 Resistance Study Group, Microbiology, Pharmacology and Pharmaceutical Sciences, Clinical sciences, Pharmacology and pharmaceutical sciences
Abstract: ObjectivesThe objectives of this study were to determine the prevalence and patterns of resistance to integrase strand transfer inhibitors (INSTIs) in patients experiencing virological failure on raltegravir-based ART and the impact on susceptibility to INSTIs (raltegravir, elvitegravir and dolutegravir).Patients and methodsData were collected from 502 treatment-experienced patients failing a raltegravir-containing regimen in a multicentre study. Reverse transcriptase, protease and integrase were sequenced at failure for each patient. INSTI resistance-associated mutations investigated were those included in the last ANRS genotypic algorithm (v23).ResultsAmong the 502 patients, at failure, median baseline HIV-1 RNA (viral load) was 2.9 log10 copies/mL. Patients had been previously exposed to a median of five NRTIs, one NNRTI and three PIs. Seventy-one percent harboured HIV-1 subtype B and the most frequent non-B subtype was CRF02_AG (13.3%). The most frequent mutations observed were N155H/S (19.1%), Q148G/H/K/R (15.4%) and Y143C/G/H/R/S (6.7%). At failure, viruses were considered as fully susceptible to all INSTIs in 61.0% of cases, whilst 38.6% were considered as resistant to raltegravir, 34.9% to elvitegravir and 13.9% to dolutegravir. In the case of resistance to raltegravir, viruses were considered as susceptible to elvitegravir in 11% and to dolutegravir in 64% of cases. High HIV-1 viral load at failure (P
Published: 2015

5. Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma

Author: Soulie, C, Descamps, D, Grude, M, Schneider, V, Trabaud, M-A, Morand-Joubert, L, Delaugerre, C, Montes, B, Barin, F, Ferre, V, Raymond, S, Jeulin, H, Alloui, C, Yerly, S, Pallier, C, Reigadas, S, Signori-Schmuck, A, Guigon, A, Fafi-Kremer, S, Haim-Boukobza, S, Mirand, A, Maillard, A, Vallet, S, Roussel, C, Assoumou, L, Calvez, V, Flandre, P, Marcelin, A-G, Lagier, E, Le Guillou, H, Bettinger, D, Fleury, H, Bellecave, P, Recordon-Pinson, P, Payan, C, Vabret, A, Henquell, C, Bouvier-Alias, M, de Rougemont, A, Dos Santos, G, Morand, P, Bocket, L, Rogez, S, Andre, P, Tardy, JC, Trabaud, MA, Tamalet, C, Delamare, C, Schvoerer, E, Andre-Garnier, E, Cottalorda, J, Guinard, J, Guiguon, A, Brun-Vezinet, F, Charpentier, C, Visseaux, B, Peytavin, G, Krivine, A, Si-Mohamed, A, Avettand-Fenoel, V, Marcelin, AG, Lambert-Niclot, S, Wirden, M, Chaix, ML, Amiel, C, Giraudeau, G, Brodard, V, Plantier, JC, Chaplain, C, Bourlet, T, Stoll-Keller, F, Schmitt, MP, Barth, H, Poggi, C, Izopet, J, Chaillon, A, Marque-Juillet, S, and Roque-Afonso, AM
Subjects: Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, HIV/AIDS, Infectious Diseases, Antimicrobial Resistance, Genetics, Clinical Research, Neurosciences, Infection, Adult, Anti-HIV Agents, Antiretroviral Therapy, Highly Active, Drug Resistance, Viral, Female, Genotype, HIV Infections, HIV-1, Humans, Male, Microbial Sensitivity Tests, Middle Aged, Mutation, Nervous System Diseases, Viral Load, ANRS Resistance AC11 Group, ARV, CSF, HIV, resistance, Microbiology, Pharmacology and Pharmaceutical Sciences, Clinical sciences, Pharmacology and pharmaceutical sciences
Abstract: OBJECTIVES: The neurological disorders in HIV-1-infected patients remain prevalent. The HIV-1 resistance in plasma and CSF was compared in patients with neurological disorders in a multicentre study. METHODS: Blood and CSF samples were collected at time of neurological disorders for 244 patients. The viral loads were >50 copies/mL in both compartments and bulk genotypic tests were realized. RESULTS: On 244 patients, 89 and 155 were antiretroviral (ARV) naive and ARV treated, respectively. In ARV-naive patients, detection of mutations in CSF and not in plasma were reported for the reverse transcriptase (RT) gene in 2/89 patients (2.2%) and for the protease gene in 1/89 patients (1.1%). In ARV-treated patients, 19/152 (12.5%) patients had HIV-1 mutations only in the CSF for the RT gene and 30/151 (19.8%) for the protease gene. Two mutations appeared statistically more prevalent in the CSF than in plasma: M41L (P=0.0455) and T215Y (P=0.0455). CONCLUSIONS: In most cases, resistance mutations were present and similar in both studied compartments. However, in 3.4% of ARV-naive and 8.8% of ARV-treated patients, the virus was more resistant in CSF than in plasma. These results support the need for genotypic resistance testing when lumbar puncture is performed.
Published: 2015

6. Beyond the word and image: II- Structural and functional connectivity of a common semantic system

Author: Jouen, A.L., Ellmore, T.M., Madden-Lombardi, C.J., Pallier, C., Dominey, P.F., and Ventre-Dominey, J.
Published: 2018
Full Text: View/download PDF

7. Synthesis and characterization of single-phase epitaxial Cr2N thin films by reactive magnetron sputtering

Author: Gharavi, M. A., Greczynski, G., Eriksson, F., Lu, J., Balke, B., Fournier, D., le Febvrier, A., Pallier, C., and Eklund, P.
Published: 2019
Full Text: View/download PDF

8. Depressive symptoms after hepatitis C cure and socio-behavioral correlates in aging people living with HIV (ANRS CO13 HEPAVIH)

Author: Salmon, D., Usubillaga, R., Sogni, P., Terris, B., Tremeaux, P., Katlama, C., Valantin, M.A., Stitou, H., Simon, A., Cacoub, P., Nafissa, S., Benhamou, Y., Charlotte, F., Fourati, Virologie: S., Poizot-Martin, I., Zaegel, O., Laroche, H., Tamalet, C., Pialoux, G., Chas, J., Callard, P., Bendjaballah, F., Amiel, C., Le Pendeven, C., Marchou, B., Alric, L., Barange, K., Metivier, S., Selves, J., Larroquette, F., Rosenthal, E., Infectiologie, Naqvi, A., Rio, V., Haudebourg, J., Saint-Paul, M.C., Monte, A. De, Giordanengo, V., Partouche, C., Bouchaud, O., Martin, A., Ziol, M., Baazia, Y., Iwaka-Bande, V., Gerber, A., Uzan, M., Bicart-See, A., Garipuy, D., Ferro-Collados, M.J., Virologie, Nicot, F., Gervais, A., Yazdanpanah, Y., Adle-Biassette, H., Alexandre, G., Peytavin, G., Lascoux-Combe, C., Molina, J.M., Bertheau, P., Chaix, M.L., Delaugerre, C., Maylin, S., Lacombe, K., Bottero, J., Krause, J., Girard, P.M., Wendum, D., Cervera, P., Adam, J., Viala, C., Vittecocq, D., Goujard, C., Quertainmont, Y., Teicher, E., Pallier, C., Lortholary, O., Duvivier, C., Rouzaud, C., Lourenco, J., Touam, F., Louisin, C., Avettand-Fenoel, V., Gardiennet, E., Mélard, A., Neau, D., Ochoa, A., Blanchard, E., Castet-Lafarie, S., Cazanave, C., Malvy, D., Dupon, M., Dutronc, H., Dauchy, F., Lacaze-Buzy, L., Desclaux, A., Bioulac-Sage, P., Trimoulet, P., Reigadas, S., Morlat, P., Lacoste, D., Bonnet, F., Bernard, N., Hessamfar, M., J, Paccalin, F., Martell, C., Pertusa, M.C., Vandenhende, M., Mercié, P., Pistone, T., Receveur, M.C., Méchain, M., Duffau, P., Rivoisy, C., Faure, I., Caldato, S., Bellecave, P., Tumiotto, C., Pellegrin, J.L., Viallard, J.F., Lazzaro, E., Greib, C., Zucman, D., Majerholc, C., Brollo, M., Farfour, E., Boué, F., Devoto, J. Polo, Kansau, I., Chambrin, V., Pignon, C., Berroukeche, L., Fior, R., Martinez, V., Abgrall, S., Favier, M., Deback, C., Lévy, Y., Dominguez, S., Lelièvre, J.D., Lascaux, A.S., Melica, G., Billaud, E., Raffi, F., Allavena, C., Reliquet, V., Boutoille, D., Biron, C., Lefebvre, M., Hall, N., Bouchez, S., Rodallec, A., Le Guen, L., Hemon, C., Miailhes, P., Peyramond, D., Chidiac, C., Ader, F., Biron, F., Boibieux, A., Cotte, L., Ferry, T., Perpoint, T., Koffi, J., Zoulim, F., Bailly, F., Lack, P., Maynard, M., Radenne, S., Amiri, M., Valour, F., Augustin-Normand, C., Scholtes, C., Le-Thi, T.T., Piroth, L., Chavanet, P., Duong Van Huyen, M., Buisson, M., Waldner-Combernoux, A., Mahy, S., Salmon Rousseau, A., Martins, C., Aumaître, H., Galim, S., Bani-Sadr, F., Lambert, D., Nguyen, Y., Berger, J.L., Hentzien, M., Brodard, V., Rey, D., Partisani, M., Batard, M.L., Cheneau, C., Priester, M., Bernard-Henry, C., de Mautort, E., Fischer, P., Gantner, P., Fafi-Kremer, S., Roustant, F., Platterier, P., Kmiec, I., Traore, L., Lepuil, S., Parlier, S., Sicart-Payssan, V., Bedel, E., Anriamiandrisoa, S., Pomes, C., Mole, M., Bolliot, C., Catalan, P., Mebarki, M., Adda-Lievin, A., Thilbaut, P., Ousidhoum, Y., Makhoukhi, F.Z., Braik, O., Bayoud, R., Gatey, C., Pietri, M.P., Le Baut, V., Ben Rayana, R., Bornarel, D., Chesnel, C., Beniken, D., Pauchard, M., Akel, S., Lions, C., Ivanova, A., Ritleg, A.-S., Debreux, C., Chalal, L., Zelie, J., Hue, H., Soria, A., Cavellec, M., Breau, S., Joulie, A., Fisher, P., Gohier, S., Croisier-Bertin, D., Ogoudjobi, S., Brochier, C., Thoirain-Galvan, V., Le Cam, M., Wittkop, L., Esterle, L., Izopet, J., Serfaty, L., Paradis, V., Spire, B., Carrieri, P., Zaegel-Faucher, O., Meyer, L., Boufassa, F., Autran, B., Roque, A.M., Solas, C., Fontaine, H., Costagliola, D., Petrov-Sanchez, V., Levier, A., P. Carrieri, Chalouni, M., Conte, V., Dequae-Merchadou, L., Desvallées, M., Gilbert, C., Gillet, S., Guillochon, Q., Khan, C., Knight, R., Marcellin, F., Michel, L., Mora, M., Protopopescu, C., Roux, P., Barré, T., Ramier, C., Sow, A., Di Beo, V., Bureau, M., Marcellin, Fabienne, Brégigeon-Ronot, Sylvie, Ramier, Clémence, Protopopescu, Camelia, Gilbert, Camille, Di Beo, Vincent, Duvivier, Claudine, Bureau-Stoltmann, Morgane, Rosenthal, Eric, Wittkop, Linda, Salmon-Céron, Dominique, Carrieri, Patrizia, Sogni, Philippe, and Barré, Tangui
Published: 2023
Full Text: View/download PDF

9. Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus‐co‐infected patients (ANRS CO13‐HEPAVIH)

Author: Nordmann, S., Vilotitch, A., Roux, P., Esterle, L., Spire, B., Marcellin, F., Salmon‐Ceron, D., Dabis, F., Chas, J., Rey, D., Wittkop, L., Sogni, P., Carrieri, P., Salmon, D, Trimoulet, P, Izopet, J, Serfaty, L, Paradis, V, Valantin, M.A., Pialoux, G, Poizot‐Martin, I, Barange, K, Naqvi, A, Rosenthal, E, Bicart‐See, A, Bouchaud, O, Gervais, A, Lascoux‐Combe, C, Goujard, C, Lacombe, K, Duvivier, C, Vittecoq, D, Neau, D, Morlat, P, Bani‐Sadr, F, Meyer, L, Boufassa, F, Dominguez, S, Autran, B, Roque, A.M., Solas, C, Fontaine, H, Costagliola, D, Piroth, L, Simon, A, Zucman, D, Boué, F, Miailhes, P, Billaud, E, Aumaître, H, Couffin‐Cadiergues, S, Marchand, L, Salmon, D, Alagna, L, Sogni, P, Terris, B, Krivine, A, Katlama, C, Valantin, M.A., Stitou, H, Benhamou, Y, Charlotte, F, Fourati, S, Simon, A, Cacoub, P, Nafissa, S, Poizot‐Martin, I, Zaegel, O, Porcher, M, Tamalet, C, Pialoux, G, Chas, J, Slama, L, Callard, P, Bendjaballah, F, Le Pendeven, C, Marchou, B, Alric, L, Barange, K, Metivier, S, Selves, J, Larroquette, F, Rosenthal, E, Haudebourg, J, Saint‐Paul, M.C., Partouche, C, Bouchaud, O, Ziol, M, Baazia, Y, Uzan, M, Bicart‐See, A, Garipuy, D, Ferro‐Collados, M.J, Selves, J, Nicot, F, Gervais, A, Yazdanpanah, Y, Adle‐Biassette, H, Alexandre, G, Lascoux‐Combe, C, Molina, J.M, Bertheau, P, Duclos, J, Palmer, P, Lacombe, K, Campa, P, Girard, P.M, Wendum, D, Cervera, P, Adam, J, Viala, C, Goujard, C, Pallier, C, Vittecoq, D, Lortholary, O, Duvivier, C, Shoai‐Tehrani, M, Mélard, A, Neau, D, Ochoa, A, Blanchard, E, Castet‐Lafarie, S, Cazanave, C, Malvy, D, Dupon, M, Dutronc, H, Dauchy, F, Lacaze‐Buzy, L, Bioulac‐Sage, P, Trimoulet, P, Reigadas, S, Morlat, P, Lacoste, D, Bonnet, F, Bernard, N, Bonarek Hessamfar, M, Roger‐Schmeltz, J, Gellie, P, Thibaut, P, Paccalin, F, Martell, C, Carmen Pertusa, M, Vandenhende, M, Mercier, P, Malvy, D, Pistone, T, Receveur, M.C, Caldato, S, Bioulac‐Sage, P, Trimoulet, P, Reigadas, S, Pellegrin, J.L, Viallard, J.F, Lazzaro, E, Greib, C, Bioulac‐Sage, P, Trimoulet, P, Reigadas, S, Zucman, D, Majerholc, C, Guitard, F, Boué, F, Polo Devoto, J, Kansau, I, Chambrin, V, Pignon, C, Berroukeche, L, Fior, R, Martinez, V, Deback, C, Lévy, Y, Dominguez, S, Lelièvre, J.D, Lascaux, A.S, Melica, G, Billaud, E, Raffi, F, Alavena, C, Rodallec, A, Miailhes, P, Peyramond, D, Chidiac, C, Ader, F, Biron, F, Boibieux, A, Cotte, L, Ferry, T, Perpoint, T, Koffi, J, Zoulim, F, Bailly, F, Lack, P, Maynard, M, Radenne, S, Amiri, M, Le‐Thi, T.T, Piroth, L, Chavanet, P, Duong Van Huyen, M, Buisson, M, Waldner‐Combernoux, A, Mahy, S, Binois, R, Simonet‐Lann, A.L, Croisier‐Bertin, D, Aumaître, H, Bani‐Sadr, F, Lambert, D, Nguen, Y, Rouger, C, Berger, J.L, Partrisiani, M, Gautner, P, Batard, M.L, Beniken, D, Lupin, C, Lions, C, Ritleng, A.‐S, Honoré, P, Payssan, V, Breau, S, Joulie, A, Mole, M, Bolliot, C, Touam, F, André, F, Hue, H, Larmet, L, Brochier, C, Thoirain, V, Raho‐Moussa, M, Ogoudjobi, S, Azar, M, Bornarel, D, Gohier, S, Chesnel, C, Maradan, G, Kurkdji, P, Hadjoudj, S, Malet, M, Kmiec, I, Fischer, P, Palacin, A, Pietri, M.P, Le Baut, V, Guet, P, Le Puil, S, Mebarki, M, Fior, A, Adda‐Lievin, A, Conte, V, Delaune, J, Dequae Merchadou, L, Douiri, N, Gillet, S, Gilbert, C, Jacquet, A, Kherraz, R, Lagorse, P, Mora, M, Protopopescu, C, and Rosellini, S
Published: 2018
Full Text: View/download PDF

10. Post‐HCV cure self‐reported changes in physical activity, eating behaviours, and fatigue in people living with HIV (ANRS CO13 HEPAVIH)

Author: Marcellin, Fabienne, Di Beo, Vincent, Esterle, Laure, Abgrall, Sophie, Pialoux, Gilles, Barré, Tangui, Wittkop, Linda, Salmon‐ceron, Dominique, Sogni, Philippe, Carrieri, Patrizia, Roustant, F, Platterier, P, Kmiec, I, Traore, L, Lepuil, S, Parlier, S, Sicart‐payssan, V, Bedel, E, Anriamiandrisoa, S, Pomes, C, Mole, M, Bolliot, C, Catalan, P, Mebarki, M, Adda‐lievin, A, Thilbaut, P, Ousidhoum, Y, Makhoukhi, F.Z, Braik, O, Bayoud, R, Gatey, C, Pietri, M.P, Le Baut, V, Ben Rayana, R, Bornarel, D, Chesnel, C, Beniken, D, Pauchard, M, Akel, S, Lions, C, Ivanova, A, Ritleg, A‐s, Debreux, C, Chalal, L, Zelie, J, Hue, H, Soria, A, Cavellec, M, Breau, S, Joulie, A, Fisher, P, Gohier, S, Croisier‐bertin, D, Ogoudjobi, S, Brochier, C, Thoirain‐galvan, V, Le Cam, M, Chalouni, M, Conte, V, Dequae‐merchadou, L, Desvallees, M, Gilbert, C, Gillet, S, Knight, R, Lemboub, T, Michel, L, Mora, M, Protopopescu, C, Roux, P, Tezkratt, S, Ramier, C, Sow, A, Bureau, M, Trimoulet, P, Izopet, J, Serfaty, L, Paradis, V, Spire, B, Valantin, V., Chas, J, Zaegel‐faucher, O, Barange, K, Naqvi, A, Rosenthal, E, Bicart‐see, A, Bouchaud, O, Gervais, A, Lascoux‐combe, C, Goujard, C, Lacombe, K, Duvivier, C, Neau, D, Morlat, P, Bani‐sadr, F, Meyer, L, Boufassa, F, Autran, B, Roque, A.M, Solas, C, Fontaine, H, Costagliola, D, Piroth, L, Simon, A, Zucman, D, Boué, F, Miailhes, P, Billaud, E, Aumaître, H, Rey, D, Peytavin, G, Petrov‐sanchez, V, Levier, A, Usubillaga, R., Terris, B, Tremeaux, P, Katlama, C, Stitou, H, Cacoub, P, Nafissa, S, Benhamou, Y, Charlotte, F, Fourati, S, Poizot‐martin, I, Zaegel, O, Laroche, H, Tamalet, C, Callard, P, Bendjaballah, F, Amiel, C, Le Pendeven, C, Marchou, B, Alric, L, Metivier, S, Selves, J, Larroquette, F, Rio, V, Haudebourg, J, Saint‐paul, M.C, de Monte, A, Giordanengo, V, Partouche, C, Martin, A, Ziol, M, Baazia, Y, Iwaka‐bande, V, Gerber, A, Uzan, M, Garipuy, D, Ferro‐collados, M.J, Nicot, F, Yazdanpanah, Y, Adle‐biassette, H, Alexandre, G, Molina, J.M, Bertheau, P, Chaix, M.L, Delaugerre, C, Maylin, S, Bottero, J, Krause, J, Girard, P.M, Wendum, D, Cervera, P, Adam, J, Viala, C, Vittecocq, D, Quertainmont, Y, Teicher, E, Pallier, C, Lortholary, O, Rouzaud, C, Lourenco, J, Touam, F, Louisin, C, Avettand‐fenoel, V, Gardiennet, E, Mélard, A, Ochoa, A, Blanchard, E, Castet‐lafarie, S, Cazanave, C, Malvy, D, Dupon, M, Dutronc, H, Dauchy, F, Lacaze‐buzy, L, Desclaux, A, Bioulac‐sage, P, Reigadas, S, Lacoste, D, Bonnet, F, Bernard, N, Hessamfar, M, Paccalin, J.F, Martell, C, Pertusa, M.C, Vandenhende, M, Mercié, P, Pistone, T, Receveur, M.C, Méchain, M, Duffau, P, Rivoisy, C, Faure, I, Caldato, S, Bellecave, P, Tumiotto, C, Pellegrin, J.L, Viallard, J.F, Lazzaro, E, Greib, C, Majerholc, C, Brollo, M, Farfour, E, Polo Devoto, J, Kansau, I, Chambrin, V, Pignon, C, Berroukeche, L, Fior, R, Martinez, V, Favier, M, Deback, C, Lévy, Y, Dominguez, S, Lelièvre, J.D, Lascaux, A.S, Melica, G, Raffi, F, Allavena, C, Reliquet, V, Boutoille, D, Biron, C, Lefebvre, M, Hall, N, Bouchez, S, Rodallec, A, Le Guen, L, Hemon, C, Peyramond, D, Chidiac, C, Ader, F, Biron, F, Boibieux, A, Cotte, L, Ferry, T, Perpoint, T, Koffi, J, Zoulim, F, Bailly, F, Lack, P, Maynard, M, Radenne, S, Amiri, M, Valour, F, Augustin‐normand, C, Scholtes, C, Le‐thi, T.T, Chavanet, P, Duong van Huyen, M, Buisson, M, Waldner‐combernoux, A, Mahy, S, Salmon Rousseau, A, Martins, C, Galim, S, Lambert, D, Nguyen, Y, Berger, J.L, Hentzien, M, Brodard, V, Partisani, M, Batard, M.L, Cheneau, C, Priester, M, Bernard‐henry, C, de Mautort, E, Fischer, P, Gantner, P, Fafi‐kremer, S, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des sciences de la santé publique [Marseille] (ISSPAM), Team MORPH3EUS (INSERM U1219 - UB - ISPED), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC Bordeaux, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, AP-HP - Hôpital Antoine Béclère [Clamart], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Bordeaux [Bordeaux], Hôpital Cochin [AP-HP], Université Paris Descartes - Paris 5 (UPD5), Physiopathologie du système immunitaire (Inserm U1223), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), ANRS CO13 HEPAVIH Study Group: F Roustant, P Platterier, I Kmiec, L Traore, S Lepuil, S Parlier, V Sicart-Payssan, E Bedel, S Anriamiandrisoa, C Pomes, M Mole, C Bolliot, P Catalan, M Mebarki, A Adda-Lievin, P Thilbaut, Y Ousidhoum, F Z Makhoukhi, O Braik, R Bayoud, C Gatey, M P Pietri, V Le Baut, R Ben Rayana, D Bornarel, C Chesnel, D Beniken, M Pauchard, S Akel, C Lions, A Ivanova, A-S Ritleg, C Debreux, L Chalal, J Zelie, H Hue, A Soria, M Cavellec, S Breau, A Joulie, P Fisher, S Gohier, D Croisier-Bertin, S Ogoudjobi, C Brochier, V Thoirain-Galvan, M Le Cam, M Chalouni, V Conte, L Dequae-Merchadou, M Desvallees, C Gilbert, S Gillet, R Knight, T Lemboub, L Michel, M Mora, C Protopopescu, P Roux, S Tezkratt, C Ramier, A Sow, M Bureau, P Trimoulet, J Izopet, L Serfaty, V Paradis, B Spire, Valantin, J Chas, O Zaegel-Faucher, K Barange, A Naqvi, E Rosenthal, A Bicart-See, O Bouchaud, A Gervais, C Lascoux-Combe, C Goujard, K Lacombe, C Duvivier, D Neau, P Morlat, F Bani-Sadr, L Meyer, F Boufassa, B Autran, A M Roque, C Solas, H Fontaine, D Costagliola, L Piroth, A Simon, D Zucman, F Boué, P Miailhes, E Billaud, H Aumaître, D Rey, G Peytavin, V Petrov-Sanchez, A Levier, R Usubillaga, B Terris, P Tremeaux, C Katlama, H Stitou, P Cacoub, S Nafissa, Y Benhamou, F Charlotte, S Fourati, I Poizot-Martin, O Zaegel, H Laroche, C Tamalet, P Callard, F Bendjaballah, C Amiel, C Le Pendeven, B Marchou, L Alric, S Metivier, J Selves, F Larroquette, V Rio, J Haudebourg, M C Saint-Paul, A De Monte, V Giordanengo, C Partouche, A Martin, M Ziol, Y Baazia, V Iwaka-Bande, A Gerber, M Uzan, D Garipuy, M J Ferro-Collados, J Selves, F Nicot, Y Yazdanpanah, H Adle-Biassette, G Alexandre, J M Molina, P Bertheau, M L Chaix, C Delaugerre, S Maylin, J Bottero, J Krause, P M Girard, D Wendum, P Cervera, J Adam, C Viala, D Vittecocq, Y Quertainmont, E Teicher, C Pallier, O Lortholary, C Rouzaud, J Lourenco, F Touam, C Louisin, V Avettand-Fenoel, E Gardiennet, A Mélard, A Ochoa, E Blanchard, S Castet-Lafarie, C Cazanave, D Malvy, M Dupon, H Dutronc, F Dauchy, L Lacaze-Buzy, A Desclaux, P Bioulac-Sage, S Reigadas, D Lacoste, F Bonnet, N Bernard, M Hessamfar, J F Paccalin, C Martell, M C Pertusa, M Vandenhende, P Mercié, D Malvy, T Pistone, M C Receveur, M Méchain, P Duffau, C Rivoisy, I Faure, S Caldato, P Bioulac-Sage, S Reigadas, P Bellecave, C Tumiotto, J L Pellegrin, J F Viallard, E Lazzaro, C Greib, P Bioulac-Sage, S Reigadas, C Majerholc, M Brollo, E Farfour, J Polo Devoto, I Kansau, V Chambrin, C Pignon, L Berroukeche, R Fior, V Martinez, M Favier, C Deback, Y Lévy, S Dominguez, J D Lelièvre, A S Lascaux, G Melica, F Raffi, C Allavena, V Reliquet, D Boutoille, C Biron, M Lefebvre, N Hall, S Bouchez, A Rodallec, L Le Guen, C Hemon, D Peyramond, C Chidiac, F Ader, F Biron, A Boibieux, L Cotte, T Ferry, T Perpoint, J Koffi, F Zoulim, F Bailly, P Lack, M Maynard, S Radenne, M Amiri, F Valour, J Koffi, F Zoulim, F Bailly, P Lack, M Maynard, S Radenne, C Augustin-Normand, C Scholtes, T T Le-Thi, P Chavanet, M Duong Van Huyen, M Buisson, A Waldner-Combernoux, S Mahy, A Salmon Rousseau, C Martins, S Galim, D Lambert, Y Nguyen, J L Berger, M Hentzien, V Brodard, M Partisani, M L Batard, C Cheneau, M Priester, C Bernard-Henry, E de Mautort, P Fischer, P Gantner, S Fafi-Kremer, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur [Paris], Statistics In System biology and Translational Medicine (SISTM), Inria Bordeaux - Sud-Ouest, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)- Bordeaux population health (BPH), and Malbec, Odile
Subjects: 0303 health sciences, Hepatology, business.industry, [SDV]Life Sciences [q-bio], Human immunodeficiency virus (HIV), MEDLINE, Physical activity, medicine.disease_cause, 3. Good health, [SDV] Life Sciences [q-bio], 03 medical and health sciences, 0302 clinical medicine, Infectious Diseases, Virology, Medicine, 030211 gastroenterology & hepatology, business, Eating behaviour, ComputingMilieux_MISCELLANEOUS, 030304 developmental biology, Clinical psychology
Abstract: International audience; No abstract available
Published: 2021
Full Text: View/download PDF

11. HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007–12: impact on susceptibility to first-line strategies

Author: Frange, Pierre, Assoumou, Lambert, Descamps, Diane, Chéret, Antoine, Goujard, Cécile, Tran, Laurent, Gousset, Marine, Avettand-Fenoël, Veronique, Bocket, Laurence, Fafi-Kremer, Samira, Guinard, Jerome, Morand-Joubert, Laurence, Nicot, Florence, Plantier, Jean-Christophe, Rogez, Sylvie, Wirden, Marc, Rouzioux, Christine, Meyer, Laurence, Chaix, Marie-Laure, Abel, S., Abraham, B., Allegre, T., Antoniotti, A., Armero, R., Audhuy, B., Aumaitre, H., Beaucaire, G., Beck-Wirth, G., Berger, J.L., Bernard, L., Beuscart, C., Bodard, L., Bouchaud, O., Boué, F., Cabane, J.-P., Cabie, A., Champagne, H., Cheneau, C., Chennebault, J.-M., Cheret, A., Christian, B., Compagnucci, A., Daneluzzi, V., Debab, Y., Dellamonica, P., Delfraissy, J.-F., Devidas, A., Diab, G., Doll, J., Drobacheff-Thebaut, M.C., Durel, A., Duvivier, C., Esnault, J.-L., Faba, L., Froguel, E., Garipuy, D., Garrait, V., Geffray, L., Genet, C., Genet, P., Gerard, L., Ghosn, J., Girard, J-.J., Girard, P.-M., Godin-Collet, C., Hochedez, P., Hoen, B., Houlbert, D., Jacomet, C., Jeantils, V., Jidar, K., Katlama, C., Klement, E., Lafeuillade, A., Lascoux, C., Launay, V., Lepretre, A., Levy, Y., Makhloufi, D., Malbec, D., Martha, B., May, T., Merrien, D., Miailhes, P., Miodovski, C., Molina, J.-M., Morlat, P., Mortier, E., Neau, D., Obadia, M., Patey, O., Pellegrin, J.-L., Perronne, V., Philibert, P., Pialoux, G., Pichancourt, G., Piroth, L., Poinsignon, Y., Poizot-Martin, I., Prazuck, T., Prendki, V., du Clary, F. Preveteau, Quinsat, D., Raffi, F., Regnier, A., Reynes, J., Rosenthal, E., Rouveix, E., Salmon, D., Salanville, F., Schmitt, J.-L., Simon-Coutellier, A., Sotto, A., Souala, F., Stein, A., Timsit, F., de Truchis, P., Uludag, A., Vaillant, O., Verdon, R., Verlesch-Langlin, A., Viard, J.-P., Vittecoq, D., Weiss, L., Yéni, P., Zucman, D., Allavena, C., Allegre, T., Amri, I., Autran, B., Bacchus, C., Blanc, C., Bonne, S., Bonnet, B., Bouchez, S., Charlier, C., Consigny, P.-H., Duvivier, C., Fourn, E., Guiroy, F., Huleux, T., Katlama, C., Lascoux-Combe, C., Leplatois, A., Lyavanc, T., Molina, J.-M., Naqvi, A., Nembot, G., Quertainmont, Y., Raffi, F., Samri, A., Schneider, L., Seang, S., Seksik, B.C.P., Shoai-Tehrani, M., Slama, L., Valentin, M.-A., Yazdanpanah, Y., Alloui, C., Amiel, C., André, P., André-Garnier, E., Anies, G., Barin, F., Bellecave, P., Bettinger, D., Bouvier-Alias, M., Brun-Vézinet, F., Calmy, A., Calvez, V., Caveng, W., Chaillon, A., Chapalay, S., Charpentier, C., Costagliola, D., Cottalorda, J., Delamare, C., Delaugerre, C., Dina, J., Santos, G. Dos, Férré, V., Flandre, P., Fleury, H., Fourati, S., Gaille, C., Giraudeau, G., Guigon, A., Haim-Boukobza, S., Lagier, E., Le Guillou-Guillemette, H., Henquell, C., Izopet, J., Lambert-Niclot, S., Leroux, M., Maillard, A., Malet, I., Marcelin, A.-G., Marque-Juillet, S., Masquelier, B., Mirand, A., Morand, P., Montes, B., Mouna, L., Noel, C., Pallier, C., Peytavin, G., Pinson-Recordon, P., Poveda, J.D., Raymond, S., Reigadas, S., Roques, A.-M., de Rougemont, A., Roussel, C., Schmitt, M.-P., Schneider, V., Schvoerer, E., Signori-Schmuck, A., Soulié, C., Tamalet, C., Tardy, J.C., Trabaud, M.-A., Vabret, A., Vallet, S., and Yerly, S.
Published: 2015
Full Text: View/download PDF

12. Beyond the word and image: characteristics of a common meaning system for language and vision revealed by functional and structural imaging

Author: Jouen, A. L., Ellmore, T. M., Madden, C. J., Pallier, C., Dominey, P. F., and Ventre-Dominey, J.
Published: 2015
Full Text: View/download PDF

13. Les grottes préhistoriques de Montmaurin, vallée de la Seygouade, Haute-Garonne

Author: Vialet A., (dir.), Boulbes, N., Charlet, C., Cailhol, D., Delpoux, M., Falguères, C., Ferré, G., Gaillard, C., Labergerie, E., Lartigot-Campin, A.-S., Lebreton, L., Mathias, C., Mestour, B., Moigne, A.-M., Ortega, A.I., Pallier, C., Perrenoud, C., Robert, J., Saos, T., TESTU, A., Thiam, D., Tombret, O., Viallet, C., Histoire naturelle de l'Homme préhistorique (HNHP), Muséum national d'Histoire naturelle (MNHN)-Université de Perpignan Via Domitia (UPVD)-Centre National de la Recherche Scientifique (CNRS), CNRS, UMR 7194 histoire naturelle de l'homme préhistorique, and Muséum national d'Histoire naturelle (MNHN)-Centre National de la Recherche Scientifique (CNRS)-Université de Perpignan Via Domitia (UPVD)
Subjects: [SHS.ARCHEO]Humanities and Social Sciences/Archaeology and Prehistory
Published: 2020

14. Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)

Author: Marcellin, Fabienne, primary, Di Beo, Vincent, additional, Aumaitre, Hugues, additional, Mora, Marion, additional, Wittkop, Linda, additional, Duvivier, Claudine, additional, Protopopescu, Camelia, additional, Lacombe, Karine, additional, Esterle, Laure, additional, Berenger, Cyril, additional, Gilbert, Camille, additional, Bouchaud, Olivier, additional, Poizot-Martin, Isabelle, additional, Sogni, Philippe, additional, Salmon-Ceron, Dominique, additional, Carrieri, Patrizia, additional, Salmon, D., additional, Wittkop, L., additional, Sogni, P., additional, Esterle, L., additional, Trimoulet, P., additional, Izopet, J., additional, Serfaty, L., additional, Paradis, V., additional, Spire, B., additional, Carrieri, P., additional, Valantin, M.A., additional, Pialoux, G., additional, Chas, J., additional, Poizot-Martin, I., additional, Barange, K., additional, Naqvi, A., additional, Rosenthal, E., additional, Bicart-See, A., additional, Bouchaud, O., additional, Gervais, A., additional, Lascoux-Combe, C., additional, Goujard, C., additional, Lacombe, K., additional, Duvivier, C., additional, Neau, D., additional, Morlat, P., additional, Bani-Sadr, F., additional, Meyer, L., additional, Boufassa, F., additional, Autran, B., additional, Roque, A.M., additional, Solas, C., additional, Fontaine, H., additional, Costagliola, D., additional, Piroth, L., additional, Simon, A., additional, Zucman, D., additional, Boué, F., additional, Miailhes, P., additional, Billaud, E., additional, Aumaître, H., additional, Rey, D., additional, Peytavin, G., additional, Petrov-Sanchez, V., additional, Lebrasseur-Longuet, D., additional, Usubillaga, R., additional, Terris, B., additional, Tremeaux, P., additional, Katlama, C., additional, Stitou, H., additional, Cacoub, P., additional, Nafissa, S., additional, Benhamou, Y., additional, Charlotte, F., additional, Fourati, S., additional, Zaegel, O., additional, Laroche, H., additional, Tamalet, C., additional, Callard, P., additional, Bendjaballah, F., additional, Amiel, C., additional, Le Pendeven, C., additional, Marchou, B., additional, Alric, L., additional, Metivier, S., additional, Selves, J., additional, Larroquette, F., additional, Rio, V., additional, Haudebourg, J., additional, Saint-Paul, M.C., additional, De Monte, A., additional, Giordanengo, V., additional, Partouche, C., additional, Martin, A., additional, Ziol, M., additional, Baazia, Y., additional, Iwaka-Bande, V., additional, Gerber, A., additional, Uzan, M., additional, Garipuy, D., additional, Ferro-Collados, M.J., additional, Nicot, F., additional, Yazdanpanah, Y., additional, Adle-Biassette, H., additional, Alexandre, G., additional, Molina, J.M., additional, Bertheau, P., additional, Chaix, M.L., additional, Delaugerre, C., additional, Maylin, S., additional, Bottero, J., additional, Krause, J., additional, Girard, P.M., additional, Wendum, D., additional, Cervera, P., additional, Adam, J., additional, Viala, C., additional, Vittecocq, D., additional, Quertainmont, Y., additional, Teicher, E., additional, Pallier, C., additional, Lortholary, O., additional, Rouzaud, C., additional, Lourenco, J., additional, Touam, F., additional, Louisin, C., additional, Avettand-Fenoel, V., additional, Gardiennet, E., additional, Mélard, A., additional, Ochoa, A., additional, Blanchard, E., additional, Castet-Lafarie, S., additional, Cazanave, C., additional, Malvy, D., additional, Dupon, M., additional, Dutronc, H., additional, Dauchy, F., additional, Lacaze-Buzy, L., additional, Desclaux, A., additional, Bioulac-Sage, P., additional, Reigadas, S., additional, Lacoste, D., additional, Bonnet, F., additional, Bernard, N., additional, Hessamfar, J, M., additional, Paccalin, F., additional, Martell, C., additional, Pertusa, M.C., additional, Vandenhende, M., additional, Mercié, P., additional, Pistone, T., additional, Receveur, M.C., additional, Méchain, M., additional, Duau, P., additional, Rivoisy, C., additional, Faure, I., additional, Caldato, S., additional, Bellecave, P., additional, Tumiotto, C., additional, Pellegrin, J.L., additional, Viallard, J.F., additional, Lazzaro, E., additional, Greib, C., additional, Majerholc, C., additional, Brollo, M., additional, Farfour, E., additional, Polo Devoto, J., additional, Kansau, I., additional, Chambrin, V., additional, Pignon, C., additional, Berroukeche, L., additional, Fior, R., additional, Martinez, V., additional, Abgrall, S., additional, Favier, M., additional, Deback, C., additional, Lévy, Y., additional, Dominguez, S., additional, Lelièvre, J.D., additional, Lascaux, A.S., additional, Melica, G., additional, Raffi, F., additional, Allavena, C., additional, Reliquet, V., additional, Boutoille, D., additional, Biron, C., additional, Lefebvre, M., additional, Hall, N., additional, Bouchez, S., additional, Rodallec, A., additional, Le Guen, L., additional, Hemon, C., additional, Peyramond, D., additional, Chidiac, C., additional, Ader, F., additional, Biron, F., additional, Boibieux, A., additional, Cotte, L., additional, Ferry, T., additional, Perpoint, T., additional, Koffi, J., additional, Zoulim, F., additional, Bailly, F., additional, Lack, P., additional, Maynard, M., additional, Radenne, S., additional, Amiri, M., additional, Valour, F., additional, Augustin-Normand, C., additional, Scholtes, C., additional, Le-Thi, T.T., additional, Chavanet, P., additional, Duong Van Huyen, M., additional, Buisson, M., additional, Waldner-Combernoux, A., additional, Mahy, S., additional, Binois, R., additional, Simonet-Lann, A.L., additional, Croisier-Bertin, D., additional, Salmon Rousseau, A., additional, Martins, C., additional, Galim, S., additional, Lambert, D., additional, Nguyen, Y., additional, Berger, J.L., additional, Hentzien, M., additional, Brodard, V., additional, Partisani, M., additional, Batard, M.L., additional, Cheneau, C., additional, Priester, M., additional, Bernard-Henry, C., additional, de Mautort, E., additional, Gantner et S Fafi-Kremer, P., additional, Roustant, F., additional, Platterier, P., additional, Kmiec, I., additional, Traore, L., additional, Lepuil, S., additional, Parlier, S., additional, Sicart-Payssan, V., additional, Bedel, E., additional, Anriamiandrisoa, S., additional, Pomes, C., additional, Mole, M., additional, Bolliot, C., additional, Catalan, P., additional, Mebarki, M., additional, Adda-Lievin, A., additional, Thilbaut, P., additional, Ousidhoum, Y., additional, Makhoukhi, F.Z., additional, Braik, O., additional, Bayoud, R., additional, Gatey, C., additional, Pietri, M.P., additional, Le Baut, V., additional, Ben Rayana, R., additional, Bornarel, D., additional, Chesnel, C., additional, Beniken, D., additional, Pauchard, M., additional, Akel, S., additional, Lions, C., additional, Ivanova, A., additional, Ritleg, A.-S., additional, Debreux, C., additional, Chalal, L., additional, Zelie, J., additional, Hue, H., additional, Soria, A., additional, Cavellec, M., additional, Breau, S., additional, Joulie, A., additional, Fisher, P., additional, Gohier, S., additional, Ogoudjobi, S., additional, Brochier, C., additional, Thoirain-Galvan, V., additional, Le Cam, M., additional, Chalouni, M., additional, Conte, V., additional, Dequae-Merchadou, L., additional, Desvallees, M., additional, Gilbert, C., additional, Gillet, S., additional, Knight, R., additional, Lemboub, T., additional, Marcellin, F., additional, Michel, L., additional, Mora, M., additional, Protopopescu, C., additional, Roux, P., additional, Tezkratt, S., additional, Barré, T., additional, Baudoin, M., additional, Santos, M., additional, Di Beo, V., additional, and Nishimwe, M., additional
Published: 2020
Full Text: View/download PDF

15. Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort

Author: Cuzin, Lise, Pugliese, Pascal, Katlama, Christine, Bani-Sadr, Firouzé, Ferry, Tristan, Rey, David, Lourenco, Jeremy, Bregigeon, Sylvie, Allavena, Clotilde, Reynes, Jacques, Cabié, André, Drobacheff-Thiébaut, C, Foltzer, A, Bouiller, K, Hustache-Mathieu, L, Chirouze, C, Lepiller, Q, Bozon, F, Babre, O, Muret, P, Laurichesse, H, Lesens, O, Vidal, M, Mrozek, N, Aumeran, C, Baud, O, Corbin, V, Letertre, P, Casanova, S, Jacomet, C, Hoen, B, Lamaury, I, Fabre, I, Curlier, E, Ouissa, R, Schepers, K, Herrmann-Storck, C, Dournon, N, Merrien, D, Perré, P, Guimard, T, Bollangier, O, Leautez, S, Morrier, M, Ader, F, Biron, F, Boibieux, A, Cotte, L, Ferry, T, Miailhes, P, Perpoint, T, Roux, S, Degroodt, S, Brochier, C, Valour, F, Chidiac, C, Dhiver, C, Mokhtari, M Saadia, Ménard, A, Dupont, H Tissot, Toméi, C, Meddeb, L, Belkhir, A, Ravaux, I, Brégigeon, S, Zaegel-Faucher, O, Obry-Roguet, V, Orticoni, M, Soavi, M, Luquet-Besson, I, Ressiot, E, Carta-Padovani, M, Ducassou, M, Bertone, H, Galie, S, Galinier, A, Monclar, M, Ritleng, A, Ivanova, A, Blanco-Betancourt, C, Lions, C, Poizot-Martin, I, Abel, S, Césaire, R, Cuzin, L, Santos, G Dos, Fagour, L, Illiaquer, M, Najioullah, F, Nguyen, D, Ouka, M, Pierre-François, S, Pasquier, J, Pircher, M, Rozé, B, Cabié, A, Atoui, N, Moing, V Le, Makinson, A, Meftah, N, de Boever, C Merle, Montes, B, Ferrer, a Montoya, Reynes, J, André, M, Boyer, L, Bouillon, M, Delestan, M, May, T, Allavena, C, Bernaud, C, Billaud, E, Biron, C, Bonnet, B, Bouchez, S, Boutoille, D, Brunet-Cartier, C, Hall, N, Jovelin, T, Morineau, P, Reliquet, V, Hue, H, Sécher, S, Cavellec, M, Soria, A, Ferré, V, André-Garnier, E, Rodallec, A, Guen, L Le, Lefebvre, M, Grossi, O, Point, P, Aubry, O, Khatchatourian, L, Raffi, F, Pugliese, P, Breaud, S, Ceppi, C, Courjon, J, Cua, E, Cottalorda, J, Dellamonica, P, Demonchy, E, Monte, a De, Durant, J, Etienne, C, Ferrando, S, Fuzibet, J, Garraffo, R, Joulie, A, Risso, K, Mondain, V, Naqvi, A, Oran, N, Perbost, I, Pillet, S, Prouvost-Keller, B, Pradier, C, Wehrlen-Pugliese, S, Rio, V, Rosenthal, E, Sausse, S, Zouzou, G, Hocqueloux, L, Cheret, A, Goujard, C, Quertainmont, Y, Teicher, E, Lerolle, N, Vittecoq, D, Deradji, O, Fourreau, F, Pallier, C, Barrail-Tran, A, Landman, R, Joly, V, Rioux, C, Lariven, S, Gervais, A, Lescure, F, Matheron, S, Louni, F, Godard, C, Julia, Z, Chansombat, M, Rahli, D, Mackoumbou-Nkouka, C, Charpentier, C, Descamps, D, Peytavin, G, Yazdanpanah, Y, Consigny, P, Cessot, G, Bossi, P, Goesch, J, Gilquin, J, Benabdelmoumen, G, Lanternier, F, Charlier, C, Amazzough, K, Henry, B, Pilmis, B, Rouzaud, C, Morgand, M, Touam, F, Louisin, C, Duvivier, C, Lortholary, O, Guery, R, Danion, F, Lourenco, J, Parize, P, Etienne, N, Launay, M, Rouzioux, C, Avettand Fenoel, V, Valantin, M, Flandre, P, Caby, F, Tubiana, R, Agher, R, Seang, Sophie, Schneider, L, Palich, R, Blanc, C, Katlama, C, Berger, J, N’guyen, Y, Lambert, D, Lebrun, D, Kmiec, I, Hentzien, M, Brodard, V, Bani-Sadr, F, Botelho-Nevers, E, Gagneux-Brunon, A, Frésard, A, Lucht, F, Fischer, P, Partisani, M, Cheneau, C, Priester, M, Batard, M, Bernard-Henry, C, de Mautort, E, Rey, D, Alvarez, M, Biezunski, N, Debard, A, Delpierre, C, Lansalot, P, Lelièvre, L, Martin-Blondel, G, Metsu, D, Piffaut, M, Porte, L, Saune, K, Delobel, P, Ajana, F, Alcaraz, I, Baclet, V, Boucher, A, Choisy, P, Huleux, T, Lafon-Desmurs, B, Melliez, H, Meybeck, A, Pasquet, A, Pradier, M, Robineau, O, Viget, N, Valette, M, Pathogénie des Staphylocoques – Staphylococcal Pathogenesis (StaPath), Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service d'Immuno-hématologie clinique [Hôpital Sainte Marguerite - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Service de Maladies Infectieuses et Tropicales, Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Département Maladies Infectieuses et Tropicales, Hôpital Universitaire, Montpellier, France, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de maladies infectieuses et tropicales [Nantes], Université de Nantes (UN)-Hôtel-Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), Service de Maladies Infectieuses [Nice], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Universitaire de Reims (CHU Reims), Laboratoire de Virologie Médicale et Moléculaire - EA 4684 (CardioVir), Université de Reims Champagne-Ardenne (URCA)-Centre Hospitalier Universitaire de Reims (CHU Reims)-SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV), CHU Strasbourg, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Service de Maladies Infectieuses et Tropicales [Fort-de-France, Martinique], CHU de la Martinique [Fort de France]-Hôpital Pierre Zobda-Quitman [CHU de la Martinique], CHU de la Martinique [Fort de France]-Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique], Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), service de maladies infectieuses CHU J Minjoz Besancon, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service des Maladies Infectieuses et Tropicales [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, CCLIN Sud-Est – Centre de Coordination de la Lutte contre les Infections Nosocomiales Sud-Est, Montpellier Research in Management (MRM), Université Montpellier 1 (UM1)-Groupe Sup de Co Montpellier (GSCM) - Montpellier Business School-Université Paul-Valéry - Montpellier 3 (UPVM)-Université de Montpellier (UM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université de Perpignan Via Domitia (UPVD), Hosp Civils Lyon, Serv Malad Infect, Lyon, France, Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Equipe 15, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Service de Maladies Infectieuses et Tropicales [Hôpital de la Croix-Rousse - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Istituto Nazionale di Fisica Nucleare [Sezione di Roma 1] (INFN), Istituto Nazionale di Fisica Nucleare, Service d'immuno-hématologie clinique (CISIH), Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Assistance Publique - Hôpitaux de Marseille (APHM), Clinique Pasteur [Toulouse], Neurobiologie, plasticité tissulaire et métabolisme énergétique (NPTME), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), DDSIS 76, Système membranaires, photobiologie, stress et détoxication (SMPSD), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), CHU Fort de France, Virologie et pathogenèse virale (VPV), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, CHU Fort de France-CHU de la Martinique [Fort de France]-Hôpital Pierre Zobda-Quitman [CHU de la Martinique], CHU de la Martinique [Fort de France], Cliniques Universitaires UCL Mont-Godinne, CHU Pontchaillou [Rennes], Service des Maladies Infectieuses et Tropicales [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre hospitalier universitaire de Nantes (CHU Nantes), Service des maladies infectieuses et tropicales [CHU Nantes], Plant Biomechanics Group, Botanischer Garten, Albert-Ludwigs-Universität Freiburg, Hôtel-Dieu de Nantes, Service de virologie [CHU Nantes], Chercheur indépendant, Service de chirurgie pédiatrique [Hôpital Lapeyronie-Arnaud de Villeneuve], Hôpital Lapeyronie [Montpellier] (CHU), Service des maladies infectieuses, Centre Hospitalier Universitaire de Nice (CHU Nice)-University Hospital, CHU Nice [Cimiez], Hôpital Cimiez [Nice] (CHU), Centre Hospitalier Universitaire de Nice (CHU Nice), Hopital l'Archet, Centre d'Information et de Soins de I'Immunodéficience Humaine (CISIH). Hôpital l'Archet 1, Hôpital l'Archet, Evelina London Children's Hospital, Hôpital Bicêtre, Hôpital Bicêtre-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11), Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Service de Maladies Infectieuses et Tropicales [CHU Bicêtre], AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Neuroimagerie cognitive (LCogn), Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Registre EPIMAD, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie, Centre d'Etudes Lasers Intenses et Applications (CELIA), Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université de Bordeaux (UB), Pharmacie de l'Hôpital Bichat, UMR CNRS 8179, Université de Lille, Sciences et Technologies-Centre National de la Recherche Scientifique (CNRS), CHU Necker - Enfants Malades [AP-HP], Université Paris Descartes - Paris 5 (UPD5), Centre d'infectiologie Necker-Pasteur [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut Pasteur [Paris], Service des Maladies infectieuses et tropicales [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de rhumatologie [Strasbourg], CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], Laboratoire de Virologie [CHU Necker], Service des maladies infectieuses et tropicales [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Saint-Etienne, Institut de pharmacologie moléculaire et cellulaire (IPMC), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Toulouse [Toulouse], Centre Hospitalier Tourcoing, CHU de Fort de France, Centre National de la Recherche Scientifique (CNRS), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service Maladies infectieuses et tropicales [CHU Toulouse], Pôle Inflammation, infection, immunologie et loco-moteur [CHU Toulouse] (Pôle I3LM Toulouse), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université de Reims Champagne-Ardenne (URCA)-Université de Reims Champagne-Ardenne (URCA), Laboratoire Chrono-environnement (UMR 6249) (LCE), Université Paul-Valéry - Montpellier 3 (UPVM)-Université de Perpignan Via Domitia (UPVD)-Groupe Sup de Co Montpellier (GSCM) - Montpellier Business School-Université de Montpellier (UM), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS), Université Claude Bernard Lyon 1 (UCBL), Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université de Bordeaux (UB)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Institut Pasteur [Paris] (IP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Université Nice Sophia Antipolis (1965 - 2019) (UNS), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Assistance Publique-Hôpitaux de Marseille (AP-HM), Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Pôle des Maladies Infectieuses et Tropicales Clinique et Biologique, Fédération de Bactériologie-Hygiène-Virologie, Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Université Montpellier 1 (UM1), Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Recherche pour le Développement (IRD [France-Sud]), Université de Montpellier (UM), Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques et émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Service de Médecine interne, Maladies Infectieuses et Immunologie Clinique [Reims], Stratégies thérapeutiques contre l'infection VIH et les maladies virales associées [iPLesp] (THERAVIR), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Institut Pasteur [Paris]-CHU Necker - Enfants Malades [AP-HP], and Service de Maladies Infectieuses et Tropicales [CHU Pitié-Salpêtrière]
Subjects: Male, 0301 basic medicine, [SDV]Life Sciences [q-bio], Integrase inhibitor, HIV Infections, Quinolones, Piperazines, Cohort Studies, chemistry.chemical_compound, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Abacavir, Antiretroviral Therapy, Highly Active, Public Health Surveillance, Pharmacology (medical), Prospective Studies, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Antiinfective agent, Elvitegravir, Mental Disorders, Cobicistat, Viral Load, 3. Good health, Infectious Diseases, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Dolutegravir, Female, France, Heterocyclic Compounds, 3-Ring, medicine.drug, Microbiology (medical), medicine.medical_specialty, Pyridones, 030106 microbiology, 03 medical and health sciences, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Raltegravir Potassium, Internal medicine, Oxazines, medicine, Humans, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, HIV Integrase Inhibitors, Pharmacology, business.industry, [SCCO.NEUR]Cognitive science/Neuroscience, Raltegravir, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, CD4 Lymphocyte Count, Discontinuation, chemistry, Nervous System Diseases, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: OBJECTIVES To analyse the frequency and causes of treatment discontinuation in patients who were treated with an integrase strand transfer inhibitor (INSTI), with a focus on neuropsychiatric adverse events (NPAEs). METHODS Patients in 18 HIV reference centres in France were prospectively included in the Dat'AIDS cohort. Data were collected from all patients starting an INSTI-containing regimen between 1 January 2006 and 31 December 2016. All causes of INSTI-containing regimen discontinuations were analysed, and patients' characteristics related to discontinuation due to NPAEs were sought. RESULTS INSTIs were prescribed to 21315 patients: 6274 received dolutegravir, 3421 received elvitegravir boosted by cobicistat, and 11620 received raltegravir. Discontinuation was observed in 12.5%, 20.2% and 50.9% of the dolutegravir-, elvitegravir- and raltegravir-treated patients, respectively (P
Published: 2019
Full Text: View/download PDF

16. Performance of genotypic algorithms for predicting tropism for HIV-1 CRF01_AE recombinant

Author: Soulie, C., Morand-Joubert, L., Cottalorda, J., Charpentier, C., Bellecave, P., Le Guen, L., Yerly, S., Montes, B., Fafi-Kremer, S., Dina, J., Avettand-Fenoel, V., Amiel, C., Roussel, C., Pallier, C., Zafilaza, K., Sayon, S., Signori-Schmuck, A., Mirand, A., Trabaud, M.A., Berger, S., Calvez, V., and Marcelin, A.G.
Published: 2018
Full Text: View/download PDF

17. Microstructure and thermoelectric properties of CrN and CrN/Cr 2 N thin films

Author: Gharavi, M, Kerdsongpanya, S, Schmidt, S., Eriksson, F, Nong, N, Lu, J., Balke, B, Fournier, D., Belliard, Laurent, Le Febvrier, A., Pallier, C., Eklund, P, Institute for Tropospheric Research (IFT), State Key Laboratory for Mesoscopic Physics, and Electron Microscopy Laboratory, Peking University [Beijing], Acoustique pour les nanosciences (INSP-E3), Institut des Nanosciences de Paris (INSP), Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Department of Physics, Chemistry and Biology [Linköping] (IFM), and Linköping University (LIU)
Subjects: [PHYS.COND.CM-MS]Physics [physics]/Condensed Matter [cond-mat]/Materials Science [cond-mat.mtrl-sci], ComputingMilieux_MISCELLANEOUS
Abstract: International audience
Published: 2018
Full Text: View/download PDF

18. Microstructure and Thermoelectric Properties of CrN and CrN/Cr2N Thin Films

Author: Gharavi, M. A., Kerdsongpanya, S., Schmidt, S., Eriksson, F., V. Nong, N., Lu, J., Fournier, D., Belliard, L., Febvrier, A. le, Pallier, C., Eklund, P., Gharavi, M. A., Kerdsongpanya, S., Schmidt, S., Eriksson, F., V. Nong, N., Lu, J., Fournier, D., Belliard, L., Febvrier, A. le, Pallier, C., and Eklund, P.
Abstract: CrN thin films with an N/Cr ratio of 95% were deposited by reactive magnetron sputtering onto (0 0 0 1) sapphire substrates. X-ray diffraction and pole figure texture analysis show CrN (1 1 1) epitaxial growth in a twin domain fashion. By changing the nitrogen versus argon gas flow mixture and the deposition temperature, thin films with different surface morphologies ranging from grainy rough textures to flat and smooth films were prepared. These parameters can also affect the CrN x system, with the film compound changing between semiconducting CrN and metallic Cr2N through the regulation of the nitrogen content of the gas flow and the deposition temperature at a constant deposition pressure. Thermoelectric measurements (electrical resistivity and Seebeck coefficient), scanning electron microscopy, and transmission electron microscopy imaging confirm the changing electrical resistivity between 0.75 and 300 , the changing Seebeck coefficient values between 140 and 230 , and the differences in surface morphology and microstructure as higher temperatures result in lower electrical resistivity while gas flow mixtures with higher nitrogen content result in single phase cubic CrN.
Published: 2018

19. HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes

Author: Reigadas, S., Marcelin, A. G., Houssaïni, A., Yerly, S., Descamps, D., Plantier, J. C., Ruffault, A., Amiel, C., Trabaud, M. A., Flandre, Philippe, Fleury, H., Masquelier, B., Roussel, C., Alloui, C., Leguillou-Guillemette, H., Bettinger, D., Pallier, C., Brun-Vezinet, F., Peytavin, G., Pinson, P., Vallet, S., Poveda, J. D., Mirand, A., Krivine, A., Auvray, C., de Rougemont, A., Signori-Schmuck, A., Bocket, L., Rogez, S., Tamalet, C., Schneider, V., Bouvier-Alias, M., Montes, B., Schvoerer, E., Ferré, V., Chaix, M. L., Guinard, J., Haim-Boukobza, S., Soulié, C., Flandre, P., Assoumou, L., Calvez, V., Maillard, A., Morand-Joubert, L., Chaplain, C., Delaugerre, C., Bourlet, T., Bertsch, S., Raymond, S., and Marque-Juillet, S.
Published: 2017

20. Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma

Author: Soulie, Cathia, Descamps, Diane, Grudé, Maxime, Schneider, Véronique, Trabaud, Mary-Anne, Morand-Joubert, Laurence, Delaugerre, Constance, Montes, Brigitte, Barin, Francis, Ferre, Virginie, Raymond, Stéphanie, Jeulin, Hélène, Alloui, Chakib, Yerly, Sabine, Pallier, Coralie, Reigadas, Sandrine, Signori-Schmuck, Anne, Guigon, Aurélie, Fafi-Kremer, Samira, Haïm-Boukobza, Stéphanie, Mirand, Audrey, Maillard, Anne, Vallet, Sophie, Roussel, Catherine, Assoumou, Lambert, Calvez, Vincent, Flandre, Philippe, Marcelin, Anne-Geneviève, Lagier, E., Roussel, C., Le Guillou, H., Alloui, C., Bettinger, D., Pallier, C., Fleury, H., Reigadas, S., Bellecave, P., Recordon-Pinson, P., Payan, C., Vallet, S., Vabret, A., Henquell, C., Mirand, A., Bouvier-Alias, M., de Rougemont, A., Dos Santos, G., Morand, P., Signori-Schmuck, A., Bocket, L., Rogez, S., Andre, P., Tardy, J.C., Trabaud, M.A., Tamalet, C., Delamare, C., Montes, B., Schvoerer, E., Ferre, V., André-Garnier, E., Cottalorda, J., Guinard, J., Guiguon, A., Descamps, D., Brun-Vézinet, F., Charpentier, C., Visseaux, B., Peytavin, G., Krivine, A., Si-Mohamed, A., Avettand-Fenoel, V., Marcelin, A.G., Calvez, V., Lambert-Niclot, S., Soulié, C., Wirden, M., Morand-Joubert, L., Delaugerre, C., Chaix, M.L., Amiel, C., Schneider, V., Giraudeau, G., Brodard, V., Maillard, A., Plantier, J.C., Chaplain, C., Bourlet, T., Fafi-Kremer, S., Stoll-Keller, F., Schmitt, M.P., Barth, H., Yerly, S., Poggi, C., Izopet, J., Raymond, S., Barin, F., Chaillon, A., Marque-Juillet, S., Roque-Afonso, A.M., Haïm-Boukobza, S., Flandre, P., Grudé, M., Assoumou, L., Costagliola, D., Allegre, T., Schmit, J.L., Chennebault, J. M., Bouchaud, O., Magy-Bertrand, N., Delfraissy, J.F., Dupon, M., Morlat, P., Neau, D., Ansart, S., Jaffuel, S., Verdon, R., Jacomet, C., Lévy, Y., Dominguez, S., Chavanet, P., Piroth, L., Cabié, A., Leclercq, P., Ajana, F., Cheret, A., Weinbreck, P., Cotte, L., Poizot-Martin, I., Ravaud, I., Christian, B., Truchetet, F., Grandidier, M., Reynes, J., May, T., Goehringer, F., Raffi, F., Dellamonica, P., Prazuck, T., Hocqueloux, L., Yéni, P., Landman, R., Launay, O., Weiss, L., Viard, J.P., Katlama, C., Simon, A., Girard, P.M., Meynard, J.L., Molina, J.M., Pialoux, G., Hoen, B., Goeger-Sow, M.T., Lamaury, I., Beaucaire, G., Jaussaud, R., Rouger, C., Michelet, C., Borsa-Lebas, F., Caron, F., Khuong, M.A., Lucht, F., Rey, D., Calmy, A., Marchou, B., Gras, G., Greder-Belan, A., Vittecoq, D., and Teicher, E.
Subjects: virus diseases
Abstract: Objectives The neurological disorders in HIV-1-infected patients remain prevalent. The HIV-1 resistance in plasma and CSF was compared in patients with neurological disorders in a multicentre study. Methods Blood and CSF samples were collected at time of neurological disorders for 244 patients. The viral loads were >50 copies/mL in both compartments and bulk genotypic tests were realized. Results On 244 patients, 89 and 155 were antiretroviral (ARV) naive and ARV treated, respectively. In ARV-naive patients, detection of mutations in CSF and not in plasma were reported for the reverse transcriptase (RT) gene in 2/89 patients (2.2%) and for the protease gene in 1/89 patients (1.1%). In ARV-treated patients, 19/152 (12.5%) patients had HIV-1 mutations only in the CSF for the RT gene and 30/151 (19.8%) for the protease gene. Two mutations appeared statistically more prevalent in the CSF than in plasma: M41L (P = 0.0455) and T215Y (P = 0.0455). Conclusions In most cases, resistance mutations were present and similar in both studied compartments. However, in 3.4% of ARV-naive and 8.8% of ARV-treated patients, the virus was more resistant in CSF than in plasma. These results support the need for genotypic resistance testing when lumbar puncture is performed
Published: 2017

21. Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study

Author: Assoumou, L., Charpentier, C., Recordon-Pinson, P., Grude, M., Pallier, C., Morand-Joubert, L., Fafi-Kremer, S., Krivine, A., Montes, B, Ferre, V., Bouvier-Alias, M., Plantier, C., Izopet, J., Trabaud, M., Yerly, S., Dufayard, J., Alloui, C., Courdavault, L., Le Guillou-Guillemette, H., Maillard, A., Amiel, C., Vabret, A., Roussel, C., Vallet, S., Guinard, J., Mirand, A., Beby-Defaux, A., Barin, F., Allardet-Servent, A., Ait-Namane, R., Wirden, M., Delaugerre, C., Calvez, V., Chaix, L., Descamps, D., Reigadas, S., Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Neuroimagerie cognitive (LCogn), Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Virologie [Strasbourg], AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre hospitalier universitaire de Nantes (CHU Nantes), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Equipe de Recherche en Physico-Chimie et Biotechnologie (ERPCB), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU), Laboratoire de Virologie Humaine et Moléculaire [Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), UR 0420 - Station de pathologie végétale, Laboratoire de pathologie forestière, Institut National de la Recherche Agronomique (INRA)-Institut National de la Recherche Agronomique (INRA), Laboratoire Universitaire de Biodiversité et Ecologie Microbienne (LUBEM), Université de Brest (UBO), CHU Orléans, CHU Clermont-Ferrand, Laboratoire Microorganismes : Génome et Environnement (LMGE), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Service de microbiologie [Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Microbiologie cellulaire et moléculaire et pathogénicité (MCMP), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Service de Virologie [CHU Bichat], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Hôpital Pellegrin, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Hôpital Cochin [AP-HP], CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Groupe de Recherche sur l'Adaptation Microbienne (GRAM 2.0), Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Département de microbiologie [CHU Rouen], CHU Rouen, Laboratoire de Virologie [Toulouse], CHU Toulouse [Toulouse], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), Hôpitaux Universitaires de Genève (HUG), Hôpital l'Archet, Hôpital Avicenne [AP-HP], Centre Hospitalier Victor Dupouy, CHU Pontchaillou [Rennes], CHU Tenon [AP-HP], CHU Amiens-Picardie, Centre Hospitalier Régional d'Orléans (CHRO), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Génétique et Ecologie des Virus, Génétique des Virus et Pathogénèse des Maladies Virales, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hopital Saint-Louis [AP-HP] (AP-HP), Centre d'Etudes Lasers Intenses et Applications (CELIA), Université de Bordeaux (UB)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Microbiologie Fondamentale et Pathogénicité (MFP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire Virologie [CHU Toulouse], Institut Fédératif de Biologie (IFB), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Université de Caen Normandie (UNICAEN), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université de Bordeaux (UB), CHU Cochin [AP-HP], T1, Laboratoire Matériaux Optiques, Photonique et Systèmes (LMOPS), CentraleSupélec-Université de Lorraine (UL)-CentraleSupélec-Université de Lorraine (UL), CHU Tenon [APHP], Station de recherches sur la vache laitière, Institut National de la Recherche Agronomique (INRA), Laboratoire Microorganismes : Génome et Environnement - Clermont Auvergne (LMGE), Université Clermont Auvergne (UCA)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7), and CHU Pitié-Salpêtrière [APHP]
Subjects: 0301 basic medicine, Microbiology (medical), Adult, Male, Genes, Viral, Genotype, Anti-HIV Agents, 030106 microbiology, HIV Infections, HIV Integrase, [SDV.MP.PRO]Life Sciences [q-bio]/Microbiology and Parasitology/Protistology, 03 medical and health sciences, 0302 clinical medicine, Drug Resistance, Multiple, Viral, HIV Protease, Antiretroviral Therapy, Highly Active, Humans, Pharmacology (medical), 030212 general & internal medicine, Treatment Failure, ComputingMilieux_MISCELLANEOUS, Pharmacology, Sequence Analysis, DNA, Middle Aged, Viral Load, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, HIV Reverse Transcriptase, 3. Good health, Infectious Diseases, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, HIV-1, RNA, Viral, Reverse Transcriptase Inhibitors, Female, France, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: Surveillance of HIV-1 resistance in treated patients with a detectable viral load (VL) is important to monitor, in order to assess the risk of spread of resistant viruses and to determine the proportion of patients who need new antiretroviral drugs with minimal cross-resistance.The HIV-1 protease and reverse transcriptase (RT) and integrase genes were sequenced in plasma samples from 782 consecutive patients on failing antiretroviral regimens, seen in 37 specialized centres in 2014. The genotyping results were interpreted using the ANRS v24 algorithm. Prevalence rates were compared with those obtained during a similar survey conducted in 2009.The protease and RT sequences were obtained in 566 patients, and the integrase sequence in 382 patients. Sequencing was successful in 60%, 78%, 78% and 87% of patients with VLs of 51-200, 201-500, 501-1000 and1000 copies/mL, respectively. Resistance to at least one antiretroviral drug was detected in 56.3% of samples. Respectively, 3.9%, 8.7%, 1.5% and 3.4% of patients harboured viruses that were resistant to any NRTI, NNRTI, PI and integrase inhibitor (INI). Resistance rates were lower in 2014 than in 2009. Resistance was detected in 48.5% of samples from patients with a VL between 51 and 200 copies/mL.In France in 2014, 90.0% of patients in AIDS care centres were receiving antiretroviral drugs and 12.0% of them had VLs50 copies/mL. Therefore, this study suggests that 6.7% of treated patients in France might transmit resistant strains. Resistance testing may be warranted in all treated patients with VL 50 copies/mL.
Published: 2017
Full Text: View/download PDF

22. Synthesis and characterization of single-phase epitaxial Cr2N thin films by reactive magnetron sputtering

Author: Gharavi, M. A., primary, Greczynski, G., additional, Eriksson, F., additional, Lu, J., additional, Balke, B., additional, Fournier, D., additional, le Febvrier, A., additional, Pallier, C., additional, and Eklund, P., additional
Published: 2018
Full Text: View/download PDF

23. Microstructure and thermoelectric properties of CrN and CrN/Cr2N thin films

Author: Gharavi, M A, primary, Kerdsongpanya, S, additional, Schmidt, S, additional, Eriksson, F, additional, Nong, N V, additional, Lu, J, additional, Balke, B, additional, Fournier, D, additional, Belliard, L, additional, le Febvrier, A, additional, Pallier, C, additional, and Eklund, P, additional
Published: 2018
Full Text: View/download PDF

24. Prévalence de l’infection par le virus de l’immunodéficience humaine et les virus des hépatites chez les personnes incarcérées en France

Author: Izquierdo, L., primary, Mellon, G., additional, Buchaillet, C., additional, Fac, C., additional, Soutière, M.P., additional, Pallier, C., additional, Dulioust, A., additional, and Roque-Afonso, A.M., additional
Published: 2018
Full Text: View/download PDF

25. Impact à un an d’un dépistage élargi des infections sexuellement transmissibles (IST) au sein d’un centre gratuit d’information, de dépistage et de diagnostic (CeGIDD) des infections par le VIH, les hépatites virales et les IST de banlieue parisienne

Author: Gatey, C., primary, Bourgeois-Nicolaos, N., additional, Rouard, C., additional, Pallier, C., additional, Richard, C., additional, Favier, M., additional, Abgrall, S., additional, Boue, F., additional, and Kansau, I., additional
Published: 2018
Full Text: View/download PDF

26. Diffusion du dolutégravir dans le liquide cérébrospinal chez les personnes vivant avec le VIH

Author: Gelé, T., primary, Barrail-Tran, A., additional, Furlan, V., additional, Pallier, C., additional, Becker, P.-H., additional, Goujard, C., additional, Taburet, A.-M., additional, Gasnault, J., additional, and Chéret, A., additional
Published: 2018
Full Text: View/download PDF

27. Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma

Author: Soulié, Cathia, Descamps, Diane, Ronique Schneider, Vé, Trabaud, Mary-Anne, Morand-Joubert, Laurence, Delaugerre, Constance, Montes, Brigitte, Barin, Francis, Ferré, Virginie, Maillard, Anne, Vallet, Sophie, Roussel, Catherine, Assoumou, Lambert, Calvez, Vincent, Flandre, Philippe, Ve, Anne-Geneviè, Jeulin, H., Guigon, A., Lagier, E., Le Guillou, H., Alloui, C., Bettinger, D., Pallier, C., Fleury, H., Reigadas, S., Bellecave, P., Recordon-Pinson, P., Payan, C., Vabret, A., Henquell, C., Mirand, A., Bouvier-Alias, M., de Rougemont, Alexis, dos Santos, G., Morand, P., Signori-Schmuck, A., Bocket, L., Rogez, S., Andre, P., Tardy, J., Tamalet, C., Delamare, C., Schvoerer, E., André-Garnier, E., Cottalorda, J., Guinard, J., Guiguon, A., Brun-Vezinet, F., Charpentier, C., Visseaux, B., Peytavin, G., Krivine, A., Si-Mohamed, A., Avettand-Fenoel, V., Marcelin, A.-G., Lambert-Niclot, S., Wirden, M., Chaix, M., Amiel, C., Schneider, V., Giraudeau, G., Brodard, V., Plantier, J., Chaplain, C., Bourlet, T., Fafi-Kremer, S., Stoll-Keller, F., Schmitt, M., Barth, H., Yerly, S., Poggi, C., Izopet, Jacques, Raymond, S., Chaillon, A., Marque-Juillet, S., Roque-Afonso, A., Haim-Boukobza, S., Grude, Maxime, Costagliola, D., Allegre, T., Schmit, J., Chennebault, J., Bouchaud, O., Magy-Bertrand, N., Delfraissy, J., Dupon, M., Morlat, P., Neau, D., Ansart, S., Jaffuel, S., Verdon, R., Jacomet, C., Levy, Y., Dominguez, S., Chavanet, P., Piroth, L., Cabié, A., Leclercq, P., Ajana, F., Cheret, A., Weinbreck, P., Cotte, L., Poizot-Martin, I., Ravaud, I., Christian, B., Truchetet, F., Grandidier, M., Reynes, J., May, T., Goehringer, F., Raffi, F., Dellamonica, P., Prazuck, T., Hocqueloux, L., Yeni, P., Landman, R., Launay, O., Weiss, L., Viard, J., Katlama, C., Simon, A., Girard, Pascal, Meynard, J., Molina, J., Pialoux, G., Hoen, B., Goeger-Sow, M., Lamaury, I., Beaucaire, G., Jaussaud, R., Rouger, C., Michelet, C., Borsa-Lebas, F., Caron, F., Khuong, M., Lucht, F., Rey, D., Calmy, A., Marchou, B., Gras, G., Greder-Belan, A., Vittecoq, D., Teicher, E., Epidémiologie, stratégies thérapeutiques et virologie cliniques dans l'infection à VIH, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Virologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de bactériologie-virologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Génétique et Ecologie des Virus, Génétique des Virus et Pathogénèse des Maladies Virales, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre national de référence du VIH INSERM U966, Université de Tours (UT), Centre hospitalier universitaire de Nantes (CHU Nantes), CHU Pontchaillou [Rennes], Laboratoire de Parasitologie et Mycologiede [CHRU Brest], Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Service de bactériologie-virologie [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau, Modélisation mathématique, calcul scientifique (MMCS), Institut Camille Jordan [Villeurbanne] (ICJ), École Centrale de Lyon (ECL), Université de Lyon-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet [Saint-Étienne] (UJM)-Centre National de la Recherche Scientifique (CNRS)-École Centrale de Lyon (ECL), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet [Saint-Étienne] (UJM)-Centre National de la Recherche Scientifique (CNRS), Service de Virologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Neuroimagerie cognitive (LCogn), Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Microbiologie Fondamentale et Pathogénicité (MFP), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Laboratoire de Virologie Humaine et Moléculaire [Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Faculté de médecine et pharmacie, CHU Clermont-Ferrand, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), UFR des Sciences de Santé (Université de Bourgogne), Université de Bourgogne (UB), Centre National de Référence des virus entériques [CHU de Dijon] (CNR virus entériques), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Laboratoire de sérologie-virologie (CHU de Dijon), Procédés Alimentaires et Microbiologiques [Dijon] (PAM), Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Université Bourgogne Franche-Comté [COMUE] (UBFC), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Biologie structurale des interactions entre virus et cellule hôte (UVHCI), Université Joseph Fourier - Grenoble 1 (UJF)-European Molecular Biology Laboratory [Grenoble] (EMBL)-Centre National de la Recherche Scientifique (CNRS), CHU Limoges, Laboratoire d'Informatique de Nantes Atlantique (LINA), Mines Nantes (Mines Nantes)-Université de Nantes (UN)-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'électronique, optoélectronique et microsystèmes (LEOM), Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (URMITE), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, Institut des sciences biologiques (INSB-CNRS)-Institut des sciences biologiques (INSB-CNRS)-Centre National de la Recherche Scientifique (CNRS), Hôtel-Dieu de Nantes, Service de chirurgie pédiatrique [Hôpital Lapeyronie-Arnaud de Villeneuve], Hôpital Lapeyronie [Montpellier] (CHU), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Equipe de Recherche en Physico-Chimie et Biotechnologie (ERPCB), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU), Interactions et dynamique des environnements de surface (IDES), Université Paris-Sud - Paris 11 (UP11)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Virologie [Strasbourg], Interaction virus-hôte et maladies du foie, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Environment and Sustainable Development Programme, European Commission - DG Research and Innovation, Centre Hospitalier Intercommunal de Toulon - La Seyne-sur-Mer, Laboratoire de Virologie [Toulouse], CHU Toulouse [Toulouse], Magnétisme et Diffusion Neutronique (MDN), Modélisation et Exploration des Matériaux (MEM), Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Centre Hospitalier du Pays d'Aix, CHU Bordeaux [Bordeaux], Fédération des Maladies Infectieuses [Bordeaux], CHU de Bordeaux Pellegrin [Bordeaux], Service de médecine interne 2 et maladies infectieuses, Unité de Maladies Infectieuses et Tropicales [CHU Caen], Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), CHU Dijon, Département d'infectiologie (CHU de Dijon), Centre d'Investigation Clinique Antilles-Guyane (CIC - Antilles Guyane), Université des Antilles et de la Guyane (UAG)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -CHU de Fort de France-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Hôpital Arnaud de Villeneuve [CHRU Montpellier], Bell Labs (BELL), Lucent Technologies, Service des Maladies Infectieuses et Tropicales [CHRU Nancy], Service des maladies infectieuses et tropicales [CHU Nantes], CIC - Biotherapie - AP-HP (cochin - Pasteur), Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Maladies Infectieuses et Tropicales [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut d’Electronique et des Systèmes (IES), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Génétique Cellulaire (LGC), Institut National de la Recherche Agronomique (INRA)-Ecole Nationale Vétérinaire de Toulouse (ENVT), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service de Médecine interne, Maladies Infectieuses et Immunologie Clinique [Reims], Centre Hospitalier Universitaire de Reims (CHU Reims), Institut d’Électronique, de Microélectronique et de Nanotechnologie - UMR 8520 (IEMN), Centrale Lille-Institut supérieur de l'électronique et du numérique (ISEN)-Université de Valenciennes et du Hainaut-Cambrésis (UVHC)-Université de Lille-Centre National de la Recherche Scientifique (CNRS)-Université Polytechnique Hauts-de-France (UPHF), CHU Saint-Etienne, CHU Strasbourg, Geneva University Hospital (HUG), Service de Maladies Infectieuses et Tropicales [CHU Bicêtre], AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Hôpital Bicêtre, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, CHU Besançon, Université de Franche-Comté (UFC), Microbiologie cellulaire et moléculaire et pathogénicité (MCMP), Laboratoire Universitaire de Biodiversité et Ecologie Microbienne (LUBEM), Université de Brest (UBO), Laboratoire Microorganismes : Génome et Environnement - Clermont Auvergne (LMGE), Université Clermont Auvergne (UCA)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de biologie structurale des interactions entre virus et cellule hôte, Université Joseph Fourier - Grenoble 1 (UJF)-Centre National de la Recherche Scientifique (CNRS), Centre d'Immunologie de Marseille - Luminy (CIML), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), INSB-INSB-Centre National de la Recherche Scientifique (CNRS), CHU Orléans, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), CHU Pitié-Salpêtrière [APHP], Service de Virologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Service de microbiologie [Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7), University of Applied Sciences Kaiserslautern, Centre de Physiopathologie Toulouse Purpan ex IFR 30 et IFR 150 (CPTP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), Hopital l'Archet, Centre d'Information et de Soins de I'Immunodéficience Humaine (CISIH). Hôpital l'Archet 1, Hôpital l'Archet, REseau national d'Investigation clinique en VACcinologie (REIVAC), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP]-Hôtel-Dieu-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de Gestion des Essais de Produits de Santé (CeNGEPS), Service des maladies infectieuses et tropicales [CHU Pitié-Salpêtrière], Estación Experimental de Pastos y Forrajes 'Indio Hatuey', Société Ragt 2N, Service des maladies infectieuses et tropicales [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), University Hospital and University Jean Monnet, Laboratoire d'Ecologie Alpine (LECA), Centre National de la Recherche Scientifique (CNRS)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Université Joseph Fourier - Grenoble 1 (UJF)-Université Grenoble Alpes (UGA), Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Bicêtre, CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Camille Jordan (ICJ), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Centre National de la Recherche Scientifique (CNRS)-École Centrale de Lyon (ECL), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire Virologie [CHU Toulouse], Institut Fédératif de Biologie (IFB), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Université de Toulouse (UT), Laboratoire Chrono-environnement (UMR 6249) (LCE), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Université de Tours, Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS)-École Centrale de Lyon (ECL), Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, European Molecular Biology Laboratory [Grenoble] (EMBL)-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF), Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), CHU de Fort de France-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française]-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -Institut National de la Santé et de la Recherche Médicale (INSERM)-Université des Antilles et de la Guyane (UAG), Hôpital Bretonneau-Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, Centre National de la Recherche Scientifique (CNRS)-Mines Nantes (Mines Nantes)-Université de Nantes (UN), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Saint-Antoine [APHP], Laboratoire de virologie, Centre National de la Recherche Scientifique (CNRS)-Université Jean Monnet [Saint-Étienne] (UJM)-École Centrale de Lyon (ECL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Université Jean Monnet [Saint-Étienne] (UJM)-École Centrale de Lyon (ECL), Université de Lyon, Université Grenoble Alpes (UGA), Station de recherches sur la vache laitière, Institut National de la Recherche Agronomique (INRA), Université Grenoble Alpes (UGA)-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes (UGA)-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Hôpital Arnaud de Villeneuve, T2, Laboratoire Matériaux Optiques, Photonique et Systèmes (LMOPS), CentraleSupélec-Université de Lorraine (UL)-CentraleSupélec-Université de Lorraine (UL), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Ecole Nationale Vétérinaire de Toulouse (ENVT), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Recherche Agronomique (INRA), Laboratoire Chrono-environnement - UFC (UMR 6249) (LCE), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Institut d’Électronique, de Microélectronique et de Nanotechnologie (IEMN) - UMR 8520 (IEMN), Centre National de la Recherche Scientifique (CNRS)-Université de Lille-Université Polytechnique Hauts-de-France (UPHF)-Ecole Centrale de Lille-Université Polytechnique Hauts-de-France (UPHF)-Institut supérieur de l'électronique et du numérique (ISEN), and de ROUGEMONT, Alexis
Subjects: Male, Drug Resistance, HIV Infections, medicine.disease_cause, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Antiretroviral Therapy, Highly Active, Genotype, Pharmacology (medical), 030212 general & internal medicine, Viral, ComputingMilieux_MISCELLANEOUS, [SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology, ddc:616, 0303 health sciences, Mutation, medicine.diagnostic_test, Proteolytic enzymes, virus diseases, Pharmacology and Pharmaceutical Sciences, Viral Load, Middle Aged, 3. Good health, ANRS Resistance AC11 Group, Infectious Diseases, Medical Microbiology, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, HIV/AIDS, ARV, Female, Infection, Viral load, Microbiology (medical), Adult, Anti-HIV Agents, Antiretroviral Therapy, CSF, Microbial Sensitivity Tests, Biology, [SDV.MP.PRO]Life Sciences [q-bio]/Microbiology and Parasitology/Protistology, Microbiology, Virus, resistance, 03 medical and health sciences, Clinical Research, Drug Resistance, Viral, medicine, Genetics, Humans, Highly Active, Gene, Pharmacology, 030306 microbiology, Lumbar puncture, Neurosciences, HIV, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, Reverse transcriptase, Immunology, HIV-1, Antimicrobial Resistance, Nervous System Diseases
Abstract: International audience; Objectives: The neurological disorders in HIV-1-infected patients remain prevalent. The HIV-1 resistance in plasma and CSF was compared in patients with neurological disorders in a multicentre study. Methods: Blood and CSF samples were collected at time of neurological disorders for 244 patients. The viral loads were .50 copies/mL in both compartments and bulk genotypic tests were realized. Results: On 244 patients, 89 and 155 were antiretroviral (ARV) naive and ARV treated, respectively. In ARV-naive patients, detection of mutations in CSF and not in plasma were reported for the reverse transcriptase (RT) gene in 2/89 patients (2.2%) and for the protease gene in 1/89 patients (1.1%). In ARV-treated patients, 19/152 (12.5%) patients had HIV-1 mutations only in the CSF for the RT gene and 30/151 (19.8%) for the protease gene. Two mutations appeared statistically more prevalent in the CSF than in plasma: M41L (P ¼ 0.0455) and T215Y (P ¼0.0455). Conclusions: In most cases, resistance mutations were present and similar in both studied compartments. However, in 3.4% of ARV-naive and 8.8% of ARV-treated patients, the virus was more resistant in CSF than in plasma. These results support the need for genotypic resistance testing when lumbar puncture is performed.
Published: 2015
Full Text: View/download PDF

28. Synthesis and characterization of single-phase epitaxial Cr2N thin films by reactive magnetron sputtering.

Author: Gharavi, M. A., Greczynski, G., Eriksson, F., Lu, J., Balke, B., Fournier, D., le Febvrier, A., Pallier, C., and Eklund, P.
Subjects: MAGNETRON sputtering, SINGLE-phase flow, ATOMIC layer epitaxial growth, STAINLESS steel, SURFACE coatings, TRANSMISSION electron microscopy
Abstract: Cr2N is commonly found as a minority phase or inclusion in stainless steel, CrN-based hard coatings, etc. However, studies on phase-pure material for characterization of fundamental properties are limited. Here, Cr2N thin films were deposited by reactive magnetron sputtering onto (0001) sapphire substrates. X-ray diffraction and pole figure texture analysis show Cr2N (0001) epitaxial growth. Scanning electron microscopy imaging shows a smooth surface, while transmission electron microscopy and X-ray reflectivity show a uniform and dense film with a density of 6.6 g cm−3, which is comparable to theoretical bulk values. Annealing the films in air at 400 °C for 96 h shows little signs of oxidation. Nano-indentation shows an elastic-plastic behavior with H = 18.9 GPa and Er = 265 GPa. The moderate thermal conductivity is 12 W m−1 K−1, and the electrical resistivity is 70 μΩ cm. This combination of properties means that Cr2N may be of interest in applications such as protective coatings, diffusion barriers, capping layers and contact materials. [ABSTRACT FROM AUTHOR]
Published: 2019
Full Text: View/download PDF

29. Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH)

Author: Carrieri, Maria Patrizia, Serfaty, Lawrence, Vilotitch, Antoine, Poizot-Martin, Isabelle, Loko, Marc-Arthur, Lions, Caroline, Salmon-Ceron, Dominique, Spire, Bruno, Dabis, François, Salmon, D, Dabis, F, Winnock, M, Sogni, P, Benhamou, Y, Trimoulet, P, Izopet, J, Paradis, V, Spire, B, Carrieri, P, Katlama, C, Pialoux, G, Valantin, M A, Bonnard, P, Rosenthal, E, Garipuy, D, Bouchaud, O, Gervais, A, Lascoux-Combe, C, Goujard, C, Lacombe, K, Duvivier, C, Vittecoq, D, Neau, D, Morlat, P, Banisadr, F, Meyer, L, Boufassa, F, Dominguez, S, Autran, B, Roque, a M, Solas, C, Fontaine, H, Serfaty, L, Chêne, G, Costagliola, D, Zucman, D, Simon, A, Billaud, E, Miailhes, P, Devoto, J Polo, Couffin-Cadiergues, S, Mehawej, H, Makhlouf, Z, Dubost, G, Tessier, F, Gibault, L, Beuvon, F, Chambon, E, Lazure, T, Krivine, A, Charlotte, F, Fourati, S, Cacoub, P, Nafissa, S, Zaegel, O, Ménard, A, Geneau, P, Tamalet, C, Bani-Sadr, F, Slama, L, Lyavanc, T, Callard, P, Bendjaballah, F, Le-Pendeven, C, Marchou, B, Alric, Laurent, Barange, K, Metivier, S, Fooladi, A, Selves, J, Nicot, F, Durant, J, Haudebourg, J, Saint-Paul, M C, Ziol, M, Baazia, Y, Uzan, M, Bicart-See, A, Ferro-Collados, M J, Yéni, P, Adle-Biassette, H, Molina, J M, Combe, C Lascoux, Bertheau, P, Duclos, J, Palmer, P, Girard, P M, Campa, P, Wendum, D, Cervera, P, Adam, J, Harchi, N, Delfraissy, J F, Quertainmont, Y, Pallier, C, Lortholary, O, Shoai-Tehrani, M, Lacaze-Buzy, L, Caldato, S, Bioulac-Sage, P, Reigadas, S, Majerholc, C, Guitard, F, Boue, F, Kansau, I, Chambrin, V, Pignon, C, Berroukeche, L, Fior, R, Martinez, V, Deback, C, Lévy, Y, Lelièvre, J D, Lascaux, a S, Melica, G, Raffi, F, Alavena, C, Rodallec, A, Peyramond, D, Chidiac, C, Ader, F, Biron, F, Boibieux, A, Cotte, L, Ferry, T, Perpoint, T, Koffi, J, Zoulim, F, Bailly, F, Lack, P, Radenne, S, Amiri, M, Beniken, D, Ritleng, a S, Azar, M, Honoré, P, Breau, S, Joulie, A, Mole, M, Bolliot, C, Chouraqui, F, Touam, F, André, F, Ouabdesselam, N, Partouche, C, Alexandre, G, Ganon, A, Champetier, A, Hue, H, Brosseau, D, Brochier, C, Thoirain, V, Rannou, M, Bornarel, D, Gillet, S, Delaune, J, Pambrun, E, Dequae-Merchadou, L, Frosch, A, Maradan, G, Cheminat, O, Marcellin, F, Mora, M, Protopopescu, C, Aix Marseille Université (AMU), Pathologies biliaires, fibrose et cancer du foie [CRSA], Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Epidemiologie-Biostatistique [Bordeaux], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux Ségalen [Bordeaux 2], AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Pharmacochimie et Biologie pour le Développement (PHARMA-DEV), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT), Pathologies biliaires, fibrose et cancer du foie [CHU Saint-Antoine], Centre de Recherche Saint-Antoine (CR Saint-Antoine), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT-FR 2599), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut National Polytechnique (Toulouse) (Toulouse INP), and Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)
Subjects: cannabis, Microbiology (medical), Adult, Male, medicine.medical_specialty, Marijuana Abuse, [SDV]Life Sciences [q-bio], Population, HIV Infections, Risk Assessment, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Surveys and Questionnaires, cohort study, medicine, Humans, 030212 general & internal medicine, Longitudinal Studies, education, education.field_of_study, biology, business.industry, Confounding, HIV, Odds ratio, Hepatitis C, Chronic, Middle Aged, biology.organism_classification, Confidence interval, 3. Good health, Infectious Diseases, Endocrinology, HCV, Cohort, Homeostatic model assessment, 030211 gastroenterology & hepatology, Female, Cannabis, France, Insulin Resistance, business, Cohort study
Abstract: International audience; Diabetes and insulin resistance (IR) is common in human immunodeficiency virus-hepatitis C virus (HIV-HCV)-coinfected patients, a population also concerned with elevated cannabis use. Cannabis has been associated with reduced IR risk in some population-based surveys. We determined whether cannabis use was consistently associated with reduced IR risk in HEPAVIH, a French nationwide cohort of HIV-HCV-coinfected patients.Methods: HEPAVIH medical and sociobehavioral data were collected (using annual self-administered questionnaires). We used 60 months of follow-up data for patients with at least 1 medical visit where IR (using homeostatic model assessment of insulin resistance [HOMA-IR]) and cannabis use were assessed. A mixed logistic regression model was used to evaluate the association between IR risk (HOMA-IR > 2.77) and cannabis use (occasional, regular, daily).Results: Among the 703 patients included in the study (1287 visits), 323 (46%) had HOMA-IR > 2.77 for at least 1 follow-up visit and 319 (45%) reported cannabis use in the 6 months before the first available visit. Cannabis users (irrespective of frequency) were less likely to have HOMA-IR > 2.77 (odds ratio [95% confidence interval], 0.4 [.2-.5]) after adjustment for known correlates/confounders. Two sensitivity analyses with HOMA-IR values as a continuous variable and a cutoff value of 3.8 confirmed the association between reduced IR risk and cannabis use.Conclusions: Cannabis use is associated with a lower IR risk in HIV-HCV-coinfected patients. The benefits of cannabis-based pharmacotherapies for patients concerned with increased risk of IR and diabetes need to be evaluated in clinical research and practice.
Published: 2014
Full Text: View/download PDF

30. HCV NS5B polymerase with a fragment of quercetagetin

Author: Guichou, J.F., primary, Ahmed-Belkacem, A., additional, Rozenn, B., additional, Nazim, N., additional, Hernandez, E., additional, Pallier, C., additional, and Pawlotsky, J.M., additional
Published: 2014
Full Text: View/download PDF

31. Seeing inferences: brain dynamics and oculomotor signatures of non-verbal deduction

Author: Ana Martín-Salguero, Carlo Reverberi, Aldo Solari, Luca Filippin, Christophe Pallier, Luca L. Bonatti, Martín-Salguero, A, Reverberi, C, Solari, A, Filippin, L, Pallier, C, and Bonatti, L
Subjects: Deduction, Reasoning, fMRI, Neural basis, Inference, Visual stimuli, Eye Tracking, Pupil Dilation, Multidisciplinary, Neurolingüística, Cognició i llenguatge, M-PSI/01 - PSICOLOGIA GENERALE, M-PSI/02 - PSICOBIOLOGIA E PSICOLOGIA FISIOLOGICA, Pensament, Psicolingüística
Abstract: Includes supplementary materials for the online appendix. We often express our thoughts through words, but thinking goes well beyond language. Here we focus on an elementary but basic thinking process, disjunction elimination, elicited by elementary visual scenes deprived of linguistic content, describing its neural and oculomotor correlates. We track two main components of a nonverbal deductive process: the construction of a logical representation (A or B), and its simplification by deduction (not A, therefore B). We identify the network active in the two phases and show that in the latter, but not in the former, it overlaps with areas known to respond to verbal logical reasoning. Oculomotor markers consistently differentiate logical processing induced by the construction of a representation, its simplification by deductive inference, and its maintenance when inferences cannot be drawn. Our results reveal how integrative logical processes incorporate novel experience in the flow of thoughts induced by visual scenes. The research was supported by the Ministerio de Ciencia e Innovación Grant PID2019-108494GB-I00 to L.L.B., by the McDonnell Foundation Network Grant: ‘The Ontogenetic Origins of Abstract Combinatorial Thought’, and by FPI BES-2017-080365 Grant to A.M.S. We thank anonymous reviewers for their comments and suggestions.
Published: 2023

32. In vivo imaging of the human brain with the Iseult 11.7-T MRI scanner.

Author: Boulant N, Mauconduit F, Gras V, Amadon A, Le Ster C, Luong M, Massire A, Pallier C, Sabatier L, Bottlaender M, Vignaud A, and Le Bihan D
Subjects: Humans, Signal-To-Noise Ratio, Image Processing, Computer-Assisted methods, Adult, Male, Magnetic Resonance Imaging methods, Magnetic Resonance Imaging instrumentation, Brain diagnostic imaging
Abstract: The understanding of the human brain is one of the main scientific challenges of the twenty-first century. In the early 2000s, the French Atomic Energy Commission launched a program to conceive and build a human magnetic resonance imaging scanner operating at 11.7 T. We have now acquired human brain images in vivo at such a magnetic field. We deployed parallel transmission tools to mitigate the radiofrequency field inhomogeneity problem and tame the specific absorption rate. The safety of human imaging at such high field strength was demonstrated using physiological, vestibular, behavioral and genotoxicity measurements on the imaged volunteers. Our technology yields T 2 and T 2 * -weighted images reaching mesoscale resolutions within short acquisition times and with a high signal and contrast-to-noise ratio., (© 2024. The Author(s).)
Published: 2024
Full Text: View/download PDF

33. Recognizing structure in novel tunes: differences between human and rats.

Author: Crespo-Bojorque P, Cauvet E, Pallier C, and Toro JM
Subjects: Humans, Rats, Animals, Rats, Long-Evans, Auditory Perception
Abstract: A central feature in music is the hierarchical organization of its components. Musical pieces are not a simple concatenation of chords, but are characterized by rhythmic and harmonic structures. Here, we explore if sensitivity to music structure might emerge in the absence of any experience with musical stimuli. For this, we tested if rats detect the difference between structured and unstructured musical excerpts and compared their performance with that of humans. Structured melodies were excerpts of Mozart's sonatas. Unstructured melodies were created by the recombination of fragments of different sonatas. We trained listeners (both human participants and Long-Evans rats) with a set of structured and unstructured excerpts, and tested them with completely novel excerpts they had not heard before. After hundreds of training trials, rats were able to tell apart novel structured from unstructured melodies. Human listeners required only a few trials to reach better performance than rats. Interestingly, such performance was increased in humans when tonality changes were included, while it decreased to chance in rats. Our results suggest that, with enough training, rats might learn to discriminate acoustic differences differentiating hierarchical music structures from unstructured excerpts. More importantly, the results point toward species-specific adaptations on how tonality is processed., (© 2024. The Author(s).)
Published: 2024
Full Text: View/download PDF

34. UniPseudo: A universal pseudoword generator.

Author: New B, Bourgin J, Barra J, and Pallier C
Subjects: Humans, Psycholinguistics, Linguistics, Reading, Language
Abstract: Pseudowords are letter strings that look like words but are not words. They are used in psycholinguistic research, particularly in tasks such as lexical decision. In this context, it is essential that the pseudowords respect the orthographic statistics of the target language. Pseudowords that violate them would be too easy to reject in a lexical decision and would not enforce word recognition on real words. We propose a new pseudoword generator, UniPseudo, using an algorithm based on Markov chains of orthographic n-grams. It generates pseudowords from a customizable database, which allows one to control the characteristics of the items. It can produce pseudowords in any language, in orthographic or phonological form. It is possible to generate pseudowords with specific characteristics, such as frequency of letters, bigrams, trigrams, or quadrigrams, number of syllables, frequency of biphones, and number of morphemes. Thus, from a list of words composed of verbs, nouns, adjectives, or adverbs, UniPseudo can create pseudowords resembling verbs, nouns, adjectives, or adverbs in any language using an alphabetic or syllabic system., Competing Interests: Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Published: 2024
Full Text: View/download PDF

35. Information-Restricted Neural Language Models Reveal Different Brain Regions' Sensitivity to Semantics, Syntax, and Context.

Author: Pasquiou A, Lakretz Y, Thirion B, and Pallier C
Abstract: A fundamental question in neurolinguistics concerns the brain regions involved in syntactic and semantic processing during speech comprehension, both at the lexical (word processing) and supra-lexical levels (sentence and discourse processing). To what extent are these regions separated or intertwined? To address this question, we introduce a novel approach exploiting neural language models to generate high-dimensional feature sets that separately encode semantic and syntactic information. More precisely, we train a lexical language model, GloVe, and a supra-lexical language model, GPT-2, on a text corpus from which we selectively removed either syntactic or semantic information. We then assess to what extent the features derived from these information-restricted models are still able to predict the fMRI time courses of humans listening to naturalistic text. Furthermore, to determine the windows of integration of brain regions involved in supra-lexical processing, we manipulate the size of contextual information provided to GPT-2. The analyses show that, while most brain regions involved in language comprehension are sensitive to both syntactic and semantic features, the relative magnitudes of these effects vary across these regions. Moreover, regions that are best fitted by semantic or syntactic features are more spatially dissociated in the left hemisphere than in the right one, and the right hemisphere shows sensitivity to longer contexts than the left. The novelty of our approach lies in the ability to control for the information encoded in the models' embeddings by manipulating the training set. These "information-restricted" models complement previous studies that used language models to probe the neural bases of language, and shed new light on its spatial organization., Competing Interests: Competing Interests: The authors have declared that no competing interests exist., (© 2023 Massachusetts Institute of Technology.)
Published: 2023
Full Text: View/download PDF

36. Does the visual word form area split in bilingual readers? A millimeter-scale 7-T fMRI study.

Author: Zhan M, Pallier C, Agrawal A, Dehaene S, and Cohen L
Subjects: Humans, Brain, Brain Mapping, Reading, Magnetic Resonance Imaging, Language
Abstract: In expert readers, a brain region known as the visual word form area (VWFA) is highly sensitive to written words, exhibiting a posterior-to-anterior gradient of increasing sensitivity to orthographic stimuli whose statistics match those of real words. Using high-resolution 7-tesla functional magnetic resonance imaging (fMRI), we ask whether, in bilingual readers, distinct cortical patches specialize for different languages. In 21 English-French bilinguals, unsmoothed 1.2-millimeters fMRI revealed that the VWFA is actually composed of several small cortical patches highly selective for reading, with a posterior-to-anterior word-similarity gradient, but with near-complete overlap between the two languages. In 10 English-Chinese bilinguals, however, while most word-specific patches exhibited similar reading specificity and word-similarity gradients for reading in Chinese and English, additional patches responded specifically to Chinese writing and, unexpectedly, to faces. Our results show that the acquisition of multiple writing systems can indeed tune the visual cortex differently in bilinguals, sometimes leading to the emergence of cortical patches specialized for a single language.
Published: 2023
Full Text: View/download PDF

37. Seeing inferences: brain dynamics and oculomotor signatures of non-verbal deduction.

Author: Martín-Salguero A, Reverberi C, Solari A, Filippin L, Pallier C, and Bonatti LL
Subjects: Language, Logic, Brain Mapping, Brain, Problem Solving
Abstract: We often express our thoughts through words, but thinking goes well beyond language. Here we focus on an elementary but basic thinking process, disjunction elimination, elicited by elementary visual scenes deprived of linguistic content, describing its neural and oculomotor correlates. We track two main components of a nonverbal deductive process: the construction of a logical representation (A or B), and its simplification by deduction (not A, therefore B). We identify the network active in the two phases and show that in the latter, but not in the former, it overlaps with areas known to respond to verbal logical reasoning. Oculomotor markers consistently differentiate logical processing induced by the construction of a representation, its simplification by deductive inference, and its maintenance when inferences cannot be drawn. Our results reveal how integrative logical processes incorporate novel experience in the flow of thoughts induced by visual scenes., (© 2023. The Author(s).)
Published: 2023
Full Text: View/download PDF

38. Graph theoretical analysis reveals the functional role of the left ventral occipito-temporal cortex in speech processing.

Author: Wang S, Planton S, Chanoine V, Sein J, Anton JL, Nazarian B, Dubarry AS, Pallier C, and Pattamadilok C
Subjects: Humans, Magnetic Resonance Imaging, Temporal Lobe, Reading, Speech, Occipital Lobe
Abstract: The left ventral occipito-temporal cortex (left-vOT) plays a key role in reading. Interestingly, the area also responds to speech input, suggesting that it may have other functions beyond written word recognition. Here, we adopt graph theoretical analysis to investigate the left-vOT's functional role in the whole-brain network while participants process spoken sentences in different contexts. Overall, different connectivity measures indicate that the left-vOT acts as an interface enabling the communication between distributed brain regions and sub-networks. During simple speech perception, the left-vOT is systematically part of the visual network and contributes to the communication between neighboring areas, remote areas, and sub-networks, by acting as a local bridge, a global bridge, and a connector, respectively. However, when speech comprehension is explicitly required, the specific functional role of the area and the sub-network to which the left-vOT belongs change and vary with the quality of speech signal and task difficulty. These connectivity patterns provide insightful information on the contribution of the left-vOT in various contexts of language processing beyond its role in reading. They advance our general understanding of the neural mechanisms underlying the flexibility of the language network that adjusts itself according to the processing context., (© 2022. The Author(s).)
Published: 2022
Full Text: View/download PDF

39. Le Petit Prince multilingual naturalistic fMRI corpus.

Author: Li J, Bhattasali S, Zhang S, Franzluebbers B, Luh WM, Spreng RN, Brennan JR, Yang Y, Pallier C, and Hale J
Subjects: Brain Mapping, Comprehension, Linguistics, Speech, Brain diagnostic imaging, Language, Magnetic Resonance Imaging
Abstract: Neuroimaging using more ecologically valid stimuli such as audiobooks has advanced our understanding of natural language comprehension in the brain. However, prior naturalistic stimuli have typically been restricted to a single language, which limited generalizability beyond small typological domains. Here we present the Le Petit Prince fMRI Corpus (LPPC-fMRI), a multilingual resource for research in the cognitive neuroscience of speech and language during naturalistic listening (OpenNeuro: ds003643). 49 English speakers, 35 Chinese speakers and 28 French speakers listened to the same audiobook The Little Prince in their native language while multi-echo functional magnetic resonance imaging was acquired. We also provide time-aligned speech annotation and word-by-word predictors obtained using natural language processing tools. The resulting timeseries data are shown to be of high quality with good temporal signal-to-noise ratio and high inter-subject correlation. Data-driven functional analyses provide further evidence of data quality. This annotated, multilingual fMRI dataset facilitates future re-analysis that addresses cross-linguistic commonalities and differences in the neural substrate of language processing on multiple perceptual and linguistic levels., (© 2022. The Author(s).)
Published: 2022
Full Text: View/download PDF

40. Neural correlates of semantic number: A cross-linguistic investigation.

Author: Dunagan D, Zhang S, Li J, Bhattasali S, Pallier C, Whitman J, Yang Y, and Hale J
Subjects: Brain Mapping, Child, Humans, Language, Magnetic Resonance Imaging, Linguistics, Semantics
Abstract: One aspect of natural language comprehension is understanding how many of what or whom a speaker is referring to. While previous work has documented the neural correlates of number comprehension and quantity comparison, this study investigates semantic number from a cross-linguistic perspective with the goal of identifying cortical regions involved in distinguishing plural from singular nouns. Three fMRI datasets are used in which Chinese, French, and English native speakers listen to an audiobook of a children's story in their native language. These languages are selected because they differ in their number semantics. Across these languages, several well-known language regions manifest a contrast between plural and singular, including the pars orbitalis, pars triangularis, posterior temporal lobe, and dorsomedial prefrontal cortex. This is consistent with a common brain network supporting comprehension across languages with overt as well as covert number-marking., (Copyright © 2022 Elsevier Inc. All rights reserved.)
Published: 2022
Full Text: View/download PDF

41. Cerebrospinal fluid exposure to bictegravir/emtricitabine/tenofovir in HIV-1-infected patients with CNS impairment.

Author: Gelé T, Chéret A, Castro Gordon A, Nkam L, Furlan V, Pallier C, Becker PH, Catalan P, Goujard C, Taburet AM, Gasnault J, Gouget H, and Barrail-Tran A
Subjects: Adenine therapeutic use, Aged, Alanine therapeutic use, Amides, Chromatography, Liquid, Emtricitabine therapeutic use, Female, Heterocyclic Compounds, 3-Ring, Humans, Middle Aged, Oxazines therapeutic use, Piperazines, Pyridones therapeutic use, Tandem Mass Spectrometry, Tenofovir therapeutic use, Anti-HIV Agents therapeutic use, HIV Infections drug therapy, HIV-1
Abstract: Objectives: The penetration of antiretroviral drugs into deep compartments, such as the CNS, is a crucial component of strategies towards an HIV cure. This study aimed to determine CSF concentrations of bictegravir, emtricitabine and tenofovir in patients with HIV-related CNS impairment (HCI) enrolled in a real-life observational study., Methods: Patients with HCI treated by optimized ART, including bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) for at least 1 month were enrolled. Plasma and CSF concentrations were measured by quality control-validated assays (LC-MS/MS). The inhibitory quotient (IQARV) was calculated as the ratio of unbound (bictegravir) or total (emtricitabine and tenofovir) concentration to half (or 90%) maximal inhibitory concentration for bictegravir (or emtricitabine and tenofovir). All numerical variables are expressed as median (range)., Results: Twenty-four patients (nine women) were enrolled. The age was 45 (26-68) years. Unbound bictegravir and total emtricitabine and tenofovir CSF concentrations were 4.4 (1.6-9.6), 84.4 (28.6-337.4) and 1.6 (0.7-4.3) ng/mL, respectively. The unbound bictegravir CSF fraction was 34% (15%-82%) versus 0.33% (0.11%-0.92%) in plasma. Three patients had an IQARV above unity for the three antiretrovirals. Factors positively associated with the CSF concentration (unbound for bictegravir) were age and total plasma concentration for the three antiretrovirals. Patients aged over 51 years had higher CSF concentrations (unbound for bictegravir)., Conclusions: We observed low CSF exposure to bictegravir, emtricitabine and tenofovir. These results suggest that BIC/FTC/TAF should be used with caution as first-line treatment for people living with HIV with HCI under 51 years of age., (© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
Published: 2021
Full Text: View/download PDF

42. Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey.

Author: Marcelin AG, Charpentier C, Bellecave P, Abdi B, Chaix ML, Ferre V, Raymond S, Fofana D, Bocket L, Mirand A, Le Guillou-Guillemette H, Montes B, Amiel C, Pallier C, Fafi-Kremer S, De Monte A, Alessandri-Gradt E, Scholtes C, Maillard A, Jeulin H, Bouvier-Alias M, Roussel C, Dos Santos G, Signori-Schmuck A, Dina J, Vallet S, Stefic K, Soulié C, Calvez V, Descamps D, and Flandre P
Subjects: Drug Resistance, Viral genetics, Heterocyclic Compounds, 3-Ring therapeutic use, Humans, Mutation, Pyridones, Raltegravir Potassium therapeutic use, HIV Infections drug therapy, HIV Integrase genetics, HIV Integrase Inhibitors pharmacology, HIV Integrase Inhibitors therapeutic use, HIV-1 genetics
Abstract: Background: Successful 2-drug regimens (2DRs) for HIV were made possible by the availability of drugs combining potency and tolerability with a high genetic barrier to resistance. How these deal with resistance development/re-emergence, compared with 3DRs, is thus of paramount importance., Materials and Methods: A national survey including patients who were either naive or experienced with any 2DR or 3DR but failing integrase strand transfer inhibitor (INSTI)-containing regimens [two consecutive plasma viral load (VL) values >50 copies/mL] was conducted between 2014 and 2019. Genotypic resistance tests were interpreted with the v28 ANRS algorithm., Results: Overall, 1104 patients failing any INSTI-containing regimen (2DRs, n = 207; 3DRs, n = 897) were analysed. Five hundred and seventy-seven (52.3%) patients were infected with a B subtype and 527 (47.3%) with non-B subtypes. Overall, 644 (58%) patients showed no known integrase resistance mutations at failure. In multivariate analysis, factors associated with the emergence of at least one integrase mutation were: high VL at failure (OR = 1.24 per 1 log10 copies/mL increase); non-B versus B subtype (OR = 1.75); low genotypic sensitivity score (GSS) (OR = 0.10 for GSS = 2 versus GSS = 0-0.5); and dolutegravir versus raltegravir (OR = 0.46). Although 3DRs versus 2DRs reached statistical significance in univariate analysis (OR = 0.59, P = 0.007), the variable is not retained in the final model., Conclusions: This study is one of the largest studies characterizing integrase resistance in patients failing any INSTI-containing 2DR or 3DR in routine clinical care and reveals factors associated with emergence of integrase resistance that should be taken into consideration in clinical management. No difference was evidenced between patients receiving a 2DR or a 3DR., (© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
Published: 2021
Full Text: View/download PDF

43. How does inattention affect written and spoken language processing?

Author: Cohen L, Salondy P, Pallier C, and Dehaene S
Subjects: Brain Mapping, Humans, Magnetic Resonance Imaging, Reading, Semantics, Temporal Lobe, Language, Speech Perception
Abstract: The classic cocktail party effect suggests that some, but probably not all levels of language processing can proceed without attention. We used whole-brain functional MRI to investigate how modality-specific and modality-independent language areas are modulated by the withdrawal of attention to another sensory modality (e.g., attending to vision during the presentation of auditory sentences, or vice-versa). We tested the hypotheses that inattention may abolish sentence-level integration and eliminate top-down effects. In both written and spoken modalities, language processing was strongly modulated by the distraction of attention, but this inattention effect varied considerably depending on the area and hierarchical level of language processing. Under inattention, a bottom-up activation remained in early modality-specific areas, particularly in superior temporal spoken-language areas, but the difference between sentences and words lists vanished. Under both attended and unattended conditions, ventral temporal cortices were activated in a top-down manner by spoken language more than by control stimuli, reaching posteriorily the Visual Word Form Area. We conclude that inattention prevents sentence-level syntactic and semantic integration, but preserves some top-down crossmodal processing, plus a large degree of bottom-up modality-specific processing, including a ventral occipito-temporal specialization for letter strings in a known alphabet., (Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Published: 2021
Full Text: View/download PDF

44. Subject-specific segregation of functional territories based on deep phenotyping.

Author: Pinho AL, Amadon A, Fabre M, Dohmatob E, Denghien I, Torre JJ, Ginisty C, Becuwe-Desmidt S, Roger S, Laurier L, Joly-Testault V, Médiouni-Cloarec G, Doublé C, Martins B, Pinel P, Eger E, Varoquaux G, Pallier C, Dehaene S, Hertz-Pannier L, and Thirion B
Subjects: Adult, Brain Mapping standards, Datasets as Topic, Echo-Planar Imaging, Female, Humans, Male, Models, Theoretical, Phenotype, Atlases as Topic, Brain Mapping methods, Cerebral Cortex diagnostic imaging, Cerebral Cortex physiology, Mental Processes physiology, Nerve Net diagnostic imaging, Nerve Net physiology
Abstract: Functional magnetic resonance imaging (fMRI) has opened the possibility to investigate how brain activity is modulated by behavior. Most studies so far are bound to one single task, in which functional responses to a handful of contrasts are analyzed and reported as a group average brain map. Contrariwise, recent data-collection efforts have started to target a systematic spatial representation of multiple mental functions. In this paper, we leverage the Individual Brain Charting (IBC) dataset-a high-resolution task-fMRI dataset acquired in a fixed environment-in order to study the feasibility of individual mapping. First, we verify that the IBC brain maps reproduce those obtained from previous, large-scale datasets using the same tasks. Second, we confirm that the elementary spatial components, inferred across all tasks, are consistently mapped within and, to a lesser extent, across participants. Third, we demonstrate the relevance of the topographic information of the individual contrast maps, showing that contrasts from one task can be predicted by contrasts from other tasks. At last, we showcase the benefit of contrast accumulation for the fine functional characterization of brain regions within a prespecified network. To this end, we analyze the cognitive profile of functional territories pertaining to the language network and prove that these profiles generalize across participants., (© 2020 The Authors. Human Brain Mapping published by Wiley Periodicals LLC.)
Published: 2021
Full Text: View/download PDF

45. Cortical encoding of linguistic constituent with and without morphosyntactic cues.

Author: Chang CHC, Dehaene S, Wu DH, Kuo WJ, and Pallier C
Subjects: Comprehension, Linguistics, Magnetic Resonance Imaging, Semantics, Brain Mapping, Cues
Abstract: This study examined the brain areas involved in combining words into larger units when there are few or no morphosyntactic cues. We manipulated constituent length in word strings of the same length under two conditions: Mandarin sentence, which had sparse morphosyntactic cues, and nominal phrase that had no morphosyntactic cues [e.g., ((honey mustard) (chicken burger))]. Contrasting sentences to word lists revealed a network that largely overlapped with the one reported in languages with rich morphosyntactic cues, including left IFGorb/IFGtri and areas along left STG/STS. Both conditions showed increased activation in left IFGtri/IFGorb in functional ROIs defined based on previous study in sentence processing, while the nominal phrases additionally revealed a constituent length effect in bilateral dorsal IFGtri, left IFGoper, left pMTG/pSTG, left IPL, and several subcortical areas, which might reflect an increased reliance on semantic and pragmatic information. Moreover, in upper left IFGtri/IFGoper and left thalamus/caudate, this effect increased with the participants' tendency to combine nouns into phrases. The absence of syntactic constraints on linguistic composition might highlight individual differences in cognitive control, which helps to integrate non-syntactic information., Competing Interests: Declaration of Competing Interest None., (Copyright © 2020 Elsevier Ltd. All rights reserved.)
Published: 2020
Full Text: View/download PDF

46. Comparison of the Abbott Alinity m and m2000 assays for the quantification of HIV-1, HCV and HBV in clinical samples.

Author: Mouna L, Pallier C, Proust S, Prégermain C, and Roque-Afonso AM
Subjects: HIV Infections virology, HIV-1 genetics, Hepacivirus genetics, Hepatitis B virology, Hepatitis B virus genetics, Hepatitis C virology, Humans, Molecular Diagnostic Techniques methods, RNA, Viral blood, Reproducibility of Results, Sensitivity and Specificity, Viral Load, HIV-1 isolation & purification, Hepacivirus isolation & purification, Hepatitis B virus isolation & purification, Molecular Diagnostic Techniques standards, Reagent Kits, Diagnostic standards
Abstract: Background: Viral load (VL) determination is an essential parameter of the management of patients infected with HIV, HBV or HCV. Many available molecular systems run on a "batch" mode while "random access" systems provide more flexibility., Objectives: We compared the performance of HIV-1, HCV and HBV quantification assays on the recently developed Abbott Alinity m system to the m2000 RealTime assays., Study Design: Plasma specimens sent for viral load determination were prospectively tested on m2000 and Alinity m systems, according to manufacturers' instructions. Additional low and high tittered samples were used to assess reproducibility., Results: Assays concordance was evaluated from 180 samples for HIV-1, 122 for HBV, and 92 for HCV. A good correlation and a linear relation over the quantification range was observed for the three markers (r > 0.974). The Alinity m assays yielded higher results with a mean quantification bias of 0.22 log cp/ml for 75 HIV-1, 0.3 log IU/ml for 79 HBV, and 0.2 log for 35 HCV samples, though results were equivalent within an allowable difference of 0.3-0.4 log. Qualitative discordance was observed for 43/180 HIV results, 10/122 HBV and 7/92 HCV and involved undetectable or low-level VL., Conclusion: The Alinity m assays have performance equivalent to m2000. Upon implementation, physicians should be aware of the relative overquantification compared to previous Abbott assays, particularly around clinical decision thresholds. With reduced turnarounds and hands-on times compared to the m2000 system, the Alinity m platform may improve significantly the laboratory workflow efficiency for the benefit of physicians and patients., Competing Interests: Declaration of Competing Interest None, (Copyright © 2020 Elsevier B.V. All rights reserved.)
Published: 2020
Full Text: View/download PDF

47. False hepatitis B and C viral serologies in patients with multiple sclerosis receiving high-dose biotin.

Author: Pourcher V, Todesco E, Dubois C, Pallier C, Lubetzki C, Louapre C, Papeix C, and Maillart E
Subjects: Antibodies, Viral analysis, Antibodies, Viral blood, Artifacts, Bacterial Proteins, Biotin analogs & derivatives, False Negative Reactions, False Positive Reactions, Hepacivirus, Hepatitis B virus, Humans, Multiple Sclerosis, Chronic Progressive virology, Biotin therapeutic use, Hepatitis B diagnosis, Hepatitis C diagnosis, Immunoassay methods, Multiple Sclerosis, Chronic Progressive drug therapy
Published: 2020
Full Text: View/download PDF

48. The black superiority effect: Black is taller than gray.

Author: Barra J, Pallier C, and New B
Subjects: Adolescent, Adult, Female, Humans, Judgment physiology, Male, Reaction Time physiology, Young Adult, Color Perception physiology, Illusions physiology, Illusions psychology, Pattern Recognition, Visual physiology, Photic Stimulation methods
Abstract: A novel illusion entitled "the letter height superiority effect" has been demonstrated. This shows that letters are perceived as being taller than pseudoletters, while in reality their objective sizes are identical. An explanation of this illusion has been proposed in the framework of the Interactive Activation Model. Indeed, we postulated that the more a feature is activated, the taller a stimulus is perceived as being. The objective of the current study was to test this postulate by manipulating feature activation through signal-to-noise ratio. We presented gray stimuli (low signal-to-noise ratio) or black ones (high signal-to-noise ratio). In a first experiment, participants judged the size of pairs of either letters or pseudoletters presented as black or gray. In a second experiment we presented pairs consisting of a letter and a pseudoletter, of identical or different colors. In a third experiment, we presented pairs of letters or pseudoletters of identical or different colors by block to test the possible effect of previous exposure on perceptual judgments. The results showed that for identical objective size, participants perceive black stimuli to be taller than gray ones and that the effects of the nature of the stimuli and their color are cumulative. The results also indicated that the effects were not due to previous exposure to color or sizes. These results confirm the Interactive Activation Model as a credible explanation for the letter height superiority effect., (Copyright © 2019 Elsevier B.V. All rights reserved.)
Published: 2020
Full Text: View/download PDF

49. Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?

Author: Visseaux B, Assoumou L, Mahjoub N, Grude M, Trabaud MA, Raymond S, Wirden M, Morand-Joubert L, Roussel C, Montes B, Bocket L, Fafi-Kremer S, Amiel C, De Monte A, Stefic K, Pallier C, Tumiotto C, Maillard A, Vallet S, Ferre V, Bouvier-Alias M, Dina J, Signori-Schmuck A, Carles MJ, Plantier JC, Meyer L, Descamps D, and Chaix ML
Subjects: Adult, Anti-HIV Agents pharmacology, Anti-HIV Agents therapeutic use, Evolution, Molecular, Female, France epidemiology, Genotype, HIV Infections drug therapy, HIV Infections virology, HIV-1 drug effects, HIV-1 pathogenicity, Humans, Male, Middle Aged, Mutation, Phylogeny, Sequence Analysis, DNA, Sexual and Gender Minorities, Viral Load, Virulence, Drug Resistance, Viral genetics, Epidemiological Monitoring, Genetic Variation, HIV Infections epidemiology, HIV-1 genetics
Abstract: Objectives: Patients with primary HIV-1 infection (PHI) are a particular population, giving important insight about ongoing evolution of transmitted drug resistance-associated mutation (TDRAM) prevalence, HIV diversity and clustering patterns. We describe these evolutions of PHI patients diagnosed in France from 2014 to 2016., Methods: A total of 1121 PHI patients were included. TDRAMs were characterized using the 2009 Stanford list and the French ANRS algorithm. Viral subtypes and recent transmission clusters (RTCs) were also determined., Results: Patients were mainly MSM (70%) living in the Paris area (42%). TDRAMs were identified among 10.8% of patients and rose to 18.6% when including etravirine and rilpivirine TDRAMs. Prevalences of PI-, NRTI-, first-generation NNRTI-, second-generation NNRTI- and integrase inhibitor-associated TDRAMs were 2.9%, 5.0%, 4.0%, 9.4% and 5.4%, respectively. In a multivariable analysis, age >40 years and non-R5 tropic viruses were associated with a >2-fold increased risk of TDRAMs. Regarding HIV diversity, subtype B and CRF02_AG (where CRF stands for circulating recombinant form) were the two main lineages (56% and 20%, respectively). CRF02_AG was associated with higher viral load than subtype B (5.83 versus 5.40 log10 copies/mL, P=0.004). We identified 138 RTCs ranging from 2 to 14 patients and including overall 41% from the global population. Patients in RTCs were younger, more frequently born in France and more frequently MSM., Conclusions: Since 2007, the proportion of TDRAMs has been stable among French PHI patients. Non-B lineages are increasing and may be associated with more virulent CRF02_AG strains. The presence of large RTCs highlights the need for real-time cluster identification to trigger specific prevention action to achieve better control of the epidemic., (© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
Published: 2020
Full Text: View/download PDF

50. Top-down activation of the visuo-orthographic system during spoken sentence processing.

Author: Planton S, Chanoine V, Sein J, Anton JL, Nazarian B, Pallier C, and Pattamadilok C
Subjects: Adult, Female, Humans, Magnetic Resonance Imaging, Male, Nerve Net diagnostic imaging, Occipital Lobe diagnostic imaging, Temporal Lobe diagnostic imaging, Young Adult, Brain Mapping, Nerve Net physiology, Occipital Lobe physiology, Reading, Speech Perception physiology, Temporal Lobe physiology
Abstract: The left ventral occipitotemporal cortex (vOT) is considered the key area of the visuo-orthographic system. However, some studies reported that the area is also involved in speech processing tasks, especially those that require activation of orthographic knowledge. These findings suggest the existence of a top-down activation mechanism allowing such cross-modal activation. Yet, little is known about the involvement of the vOT in more natural speech processing situations like spoken sentence processing. Here, we addressed this issue in a functional Magnetic Resonance Imaging (fMRI) study while manipulating the impacts of two factors, i.e., task demands (semantic vs. low-level perceptual task) and the quality of speech signals (sentences presented against clear vs. noisy background). Analyses were performed at the levels of whole brain and region-of-interest (ROI) focusing on the vOT voxels individually identified through a reading task. Whole brain analysis showed that processing spoken sentences induced activity in a large network including the regions typically involved in phonological, articulatory, semantic and orthographic processing. ROI analysis further specified that a significant part of the vOT voxels that responded to written words also responded to spoken sentences, thus, suggesting that the same area within the left occipitotemporal pathway contributes to both reading and speech processing. Interestingly, both analyses provided converging evidence that vOT responses to speech were sensitive to both task demands and quality of speech signals: Compared to the low-level perceptual task, activity of the area increased when efforts on comprehension were required. The impact of background noise depended on task demands. It led to a decrease of vOT activity in the semantic task but not in the low-level perceptual task. Our results provide new insights into the function of this key area of the reading network, notably by showing that its speech-induced top-down activation also generalizes to ecological speech processing situations., (Copyright © 2019 Elsevier Inc. All rights reserved.)
Published: 2019
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

100 results on '"Pallier C"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources